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ABSTRACT 
 Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic disease 
characterized by symptoms of urinary urgency, frequency, bladder pain, and chronic 
pelvic pain in the absence of known pathology.  Selection of appropriate treatments 
depended on the severity of the patient’s symptoms and patient’s preference. This 
review found that it is important for providers and patients to set realistic goals for 
symptom improvement when starting a new treatment.    
 The purposes of this project was to 1) conduct a substantive literature review on 
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral 
pharmacological interventions and behavioral interventions for IC/PBS, and 3) 
determine the best practice recommendation for the management of ICS/PBS in adult 
women.  An extensive review and analysis of literature published from 2002 through 
2012 was conducted to answer the following PICOT question: In women ages 18 and 
older with a diagnosis of IC/PBS, who are not pregnant (P), how do oral pharmacological 
interventions (I) compare with behavioral interventions (C) Best practice for managing 
IC/PBS in adult women ages 18 and older, evidenced by a decrease in IC/PBS symptoms 
indicated by a reduction in the patient’s ICSI and ICPI scores from baseline or patient self 
reported improvement of symptoms. (T)? 
  
  v
 Best practice management of IC/PBS begins by setting realistic goals with the 
patient for adequate symptom control and quality of life.  The literature showed that 
behavioral modification and adequate coping strategies significantly improve symptoms 
and quality of life for women with IC/PBS (Chaiken et al., 1993; Rothrock et al., 2003). 
The literature did not support the use of amitptyline, cimetidine, or hydroxyzine for 
management of symptoms of IC/PBS in women (Dimitrakov et al., 2007; Hill et al., 2008; 
Unwin, 2011).  RCTs and systematic reviews found that PPS significantly improved 
symptoms of IC/PBS and quality of life with minimal side effects and the medication was 
generally well tolerated (Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; 
Sand et al., 2008). Management of IC/PBS should focus on providing adequate relief to 
the patient with the most conservative treatments possible.
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INTRODUCTION 
 Interstitial cystitis (IC) is a chronic disease that is characterized by symptoms of 
urinary urgency, frequency, bladder pain, and chronic pelvic pain in the absence of 
known pathology (Heck, 2007).   Recently IC has assumed labels such as painful bladder 
syndrome (PBS); this term was introduced to better describe the symptom complex that 
patients with IC experience (Forrest & Moldwin, 2008).   Current literature refers to the 
disorder as IC/PBS to avoid any unnecessary confusion (Dell, 2007; Forrest & Moldwin, 
2008; Hanno et al., 2011).  The typical patient with IC/PBS is a young to middle age adult 
woman who complains of bladder pain, pelvic pain, urinary frequency and urgency, 
nocturia, dysuria and dyspareunia in the absence of abnormal findings on a urinalysis 
(UA) or urine culture (Chaiken, Blaivas, & Blaivas, 1993; Dell, 2007).   Thus, IC/PBS is 
often a diagnosis of exclusion based on clinical findings once differential diagnoses such 
as overactive bladder, urinary tract infection, endometriosis and chronic pelvic pain 
syndrome have been ruled out (Dell, 2007; Forrest & Moldwin, 2008).   
Traditionally, a cystoscopy is conducted for the diagnosis of IC/PBS.  Classic 
cystoscopic findings include glomerulrations of the bladder known as Hunner’s Ulcers 
and bleeding.  However, not all patients with IC/PBS will demonstrate these classic 
findings (Chaiken et al., 1993; Hanno et al., 2011; Theoharides, 2007).   
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The percentage of IC/PBS patients who have Hunner’s ulcers varies from five to 
fifty percent depending on the sample population studied (Klutke & Klutke, 2008; 
Rosamilia, 2005). Because cystoscopy findings among patients with IC/PBS vary, current 
evidence does not support the use of cystoscopy for the diagnosis of IC/PBS (Chaiken et 
al., 1993; Hanno et al., 2011; Onwude, 2009; Rosenberg & Hazzard, 2005; Theoharides, 
2007).  Instead, providers are encouraged to identify, assess, and monitor treatment 
progress using tools such as the O’Leary-Sant interstitial cystitis symptom index (ICSI), 
the interstitial cystitis problem index (ICPI) and the Pelvic Pain and Urgency/Frequency 
(PUF) Patient symptom scale (Dell & Butrick, 2006; Hanno et al., 2011; Nickel et al., 
2005; Theoharides, 2007).  The PUF scale is a symptom questionnaire that is validated 
for use in diagnosing IC/PBS.  A score between 0-35 is used in the PUF scale to rate 
symptoms, the higher the score the more likely a patient is to have IC/PBS (Parsons, 
2006). A score of 12 is considered by experts to be indicative of IC/PBS (Forrest & 
Mishell, 2009).  The O’Leary-Sant ICSI and ICPI have been validated for evaluating 
symptoms and problems related to IC/PBS in the patient that has already been 
diagnosed with IC/PBS, these tools are recommended for use in evaluating the 
effectiveness of treatments, however its validity for use as a diagnostic tool has not 
been studied (O'Leary, 1998; Theoharides, 2007).  These tools are primarily based on 
symptomology and do not include physical exam findings or treatment guideline 
parameters.  
 Currently, 183 treatments have been documented in the management of IC/PBS; 
no one treatment or guideline approach has been identified as the standard therapy 
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(Dell & Butrick, 2006; Onwude, 2009; Rosamilia, 2005).  Therapies for IC/PBS include 
oral medications, intravascular medications, physical therapy, electrical stimulation, 
biofeedback, dietary modifications and surgery (Hanno et al., 2011; Rosamilia, 2005; 
Theoharides, 2007). Most treatments have not been shown to significantly improve 
symptoms of IC/PBS; there is no single treatment that has been found to be effective for 
a majority of IC/PBS patients (Dell & Butrick, 2006; Hanno et al., 2011).   Clinical trials 
have studied management of IC/PBS patients with varying degrees of symptom severity 
making it difficult for providers to draw conclusions and generalize results (Theoharides, 
2007).  Selection of appropriate treatments depends on the severity of the patient’s 
symptoms and patient’s preference, it is important for providers and patients to set 
realistic goals for symptom improvement when starting a new treatment (Hanno et al., 
2011; Onwude, 2009).   
 Because of the lack of clear guidelines to aid providers in assessing and managing 
IC/PBS, it is estimated that many patients are undiagnosed, misdiagnosed, or 
mismanaged for five to seven years (Forrest & Mishell, 2009; Heck, 2007). Misdiagnosis, 
delayed diagnosis, and inappropriate management of IC/PBS leads to decreased quality 
of life and poor outcomes for patients (Forrest & Moldwin, 2008; Heck, 2007).  The first 
healthcare provider that many women with symptoms of IC/PBS are cared for by is not a 
specialist, but their primary care provider (Patel et al., 2008).  In a survey of primary care 
physicians, Clemens et al. (2010) found that many primary care physicians have 
erroneous beliefs about IC/PBS, including the belief that IC is caused by a psychiatric 
illness or and STD.  Only 67% of physicians surveyed correctly identified the hallmark 
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symptoms of IC/PBS and commonly treated patients with NSAIDS and anticholinergics, 
not recommended therapies for IC/PBS (Clemens et al., 2010).  Familiarity with IC/PBS 
and best practice guidelines assist healthcare providers in achieving better outcomes for 
women with IC/PBS.  The purposes of this project is to 1) conduct a substantive 
literature review on treatment guidelines for IC/PBS, 2) analyze the literature for 
comparing oral pharmacological interventions and behavioral interventions for IC/PBS, 
and 3) determine the best practice recommendation for the management of ICS/PBS in 
adult women, ages 18 and older.       
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE OF THE PROBLEM 
Definition  
 IC/PBS is a chronic progressive disease that is characterized by a collection of 
symptoms including urinary urgency, frequency and chronic pelvic pain in the absence 
of other explanatory pathology (Heck, 2007).   There are several definitions found in the 
literature. The Society for Urodynamics and Female Urology defines IC/PBS as an 
unpleasant sensation, described as pain pressure or discomfort perceived to be related 
to the urinary bladder and associated with lower urinary tract symptoms of more than 
six weeks duration in the absence of infection or other identifiable cause (Hanno et al., 
2011).  The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) 
developed a set of diagnostic criteria for use in clinical studies of IC/PBS.  The NIDDK 
criteria defines IC as the presence of glomerulations or Hunner’s ulcers on cystoscopy, 
and either pain associated with the bladder or urinary urgency (Forrest & Moldwin, 
2008; Hanno, 2002; Hanno et al., 2011; Onwude, 2009; Rosamilia, 2005; Theoharides, 
2007). The criteria developed by the NIDDK were developed for research purposes and 
are considered to be too restrictive for use as clinical diagnostic criteria because it is 
believed that these criteria do not capture individuals who are in early stages of IC/PBS 
(Hanno, 2002; Ibrahim, Diokno, Killinger, Carrico, & Peters, 2007; Parsons, 2002; 
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Rosenberg & Hazzard, 2005).  However, due to the lack of definitive diagnostic criteria 
the NIDDK criteria have been used in the clinical setting (Hanno, 2002). The 
International Continence Society defines PBS as the complaint of suprapubic pain 
related to bladder filling, accompanied by other symptoms such as increased urinary 
frequency in the absence of proven UTI or other obvious pathology (Rosamilia, 2005).  
Theoharides (2007) defined IC/PBS as symptoms of pain pressure or discomfort 
involving the lower abdomen and bladder relieved by voiding with urinary urgency and 
frequency in the absence of a UTI or other identifiable pathology.     
Diagnosis 
In addition to chronic pelvic pain, urinary frequency and urgency, women 
complain of nocturia, dysuria, and dyspareunia (Dell, 2007).  Many of these symptoms 
overlap with other disorder; because of this IC/PBS is a diagnosis of exclusion.  
Differential diagnoses that must be considered include chronic pelvic pain syndrome 
(CPPS), overactive bladder (OAB), urinary tract infection (UTI), irritable bowel syndrome 
(IBS), endometriosis and sexually transmitted diseases (STD) (Dell, 2007; Forrest & 
Moldwin, 2008).  
Etiology 
 The exact etiology of IC/PBS is unknown but several theories have been 
proposed including that the IC/PBS is caused by autoimmune breakdown, infections, 
neurologic disorder, and psychological factors (Klutke & Klutke, 2008).  The theory that 
is most widely accepted is the multifactorial theory.  This theory purports that there is 
initial damage to the epithelium of the bladder which leads to increased permeability to 
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cytotoxic factors resulting in chronic inflammation of the bladder lining (Burkman, 2004; 
Burrell & Hurm, 1999; Dell, 2007; Forrest & Mishell, 2009; Jamison, Dawson Timothy, & 
Helfand, 2007; Klutke & Klutke, 2008; Rosamilia, 2005).  The initial damage to the 
glycosaminoglycan (GAG) lining of the bladder can be caused by many factors including 
infection, childbirth, pelvic surgery, bladder trauma or introduction of toxins to the 
bladder (Forrest & Mishell, 2009; Klutke & Klutke, 2008).  The increased presence of 
mast cells in the bladder of women with IC/PBS suggests infectious or autoimmune 
process (Burrell & Hurm, 1999; Jamison et al., 2007).  The increased permeability of the 
bladder epithelium and continued exposure to toxins leads to chronic inflammation and 
neurogenic upregulation contributing to chronic pain, scaring of the bladder and 
decreased bladder capacity (Dell, 2007; Klutke & Klutke, 2008).   
 The average age of onset of IC/PBS is in the mid forties. However, about 25% of 
patients diagnosed are less than thirty years of age.   Recently, there have been some 
reports of pediatric cases.  However, there is scant literature available on pediatric 
IC/PBS  (Hanno, 2002; Heck, 2007).  IC/PBS affects both men and women.  It is estimated 
that 90% of the cases of IC/PBS occur in women (Heck, 2007).    
Prevalence.   
 The prevalence of IC/PBS in the general population is a number that researchers 
have struggled to ascertain. Difficulty in assessing the prevalence of IC/PBS results from 
a lack of uniform diagnostic criteria, a definitive diagnostic test, the variable 
presentation of symptoms in the early stages of IC and the overlap of symptoms with 
other common disorders (Ibrahim et al., 2007; Rosamilia, 2005; Rosenberg & Hazzard, 
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2005). To further complicate prevalence determination of IC/PBS, researchers have 
found that the prevalence varies depending on which definition of IC/PBS is used. 
Forrest and Moldwin (2008) suggested that sixty percent of patients that are diagnosed 
with IC/PBS by an expert clinician based on clinical presentation would be excluded from 
the diagnosis based on the strict NIDDK criteria. 
 Several studies have been conducted to attempt to estimate the prevalence of 
IC/PBS, using several different definitions of the disorder.  These studies have found 
various prevalence rates of IC/PBS determined by the definition of IC/PBS used in the 
study design. The RAND Interstitial Cystitis Epidemiology (RICE) study, found that 2.7% 
to 6.5% of women in the United States over the age of 18 met the symptom criteria for 
diagnosis with IC/PBS; this translates to approximately 3.4 to 7.9 million women in the 
United States (Kerr, 2009).   The range of prevalence estimates found in this study are 
due to the use of two definitions of IC/PBS a high-sensitivity definition to estimate the 
high end and a high specificity definition to estimate the low end of the range (Kerr, 
2009).   
 Rosenberg and Hazzard (2005) conducted a study of women seen in a primary 
care office for symptoms of IC/PBS such as urgency, frequency, disuria, and pelvic pain. 
They used the O’Leary-Sant IC symptom (ICSI) and problem index (ICPI) and the Pelvic 
Pain and Urgency/Frequency (PUF) patient symptom scale to evaluate the prevalence of 
IC/PBS among their patients. Their findings indicate that using the PUF scale 12.6% of 
the patient population had IC/PBS, using the O’Leary-Sant ICSI and ICPI only 0.57% of 
the population met diagnostic criteria for IC/PBS (Rosenberg & Hazzard, 2005). The 
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researchers conclude that the O’Leary-Sant indices are not designed for screening for 
IC/PBS but as a tool to evaluate progression of established IC/PBS. The PUF index, 
validated as a screening tool for IC/PBS, has increased sensitivity to identify patients 
with IC/PBS (Rosenberg & Hazzard, 2005).  
Rosenberg and Hazzard (2005) estimated that the actual prevalence of IC/PBS in 
women in a primary care setting was between 0.57% and 12.6%, the percentages 
estimated by using the PUF scale and the ICSI and ICPI.  Ibrahim, Diokno, Killinger, 
Carrico and Peters (2006) conducted their own study to determine the prevalence of 
IC/PBS using multiple definitions of IC/PBS.  Ibrahim et al. (2006) found that using the 
most restrictive definition the prevalence of IC/PBS in a community population was 
3.7%; using the least restrictive definition the prevalence was 17.3%. These researchers 
concluded with 95% confidence that the actual prevalence of IC/PBS in the general 
population is between 3.7% and 17.3%.   Using their findings, Ibrahaim et al. (2007) 
generalized this data to the population of women in the United States over age 18. They 
estimated that between 422,803 and 21,454,813 women are affected by IC/PBS 
annually.      
Costs 
 Estimates indicate that women with IC/PBS pay two to there times more for 
direct health care cost than the average woman (Stanford, Chen, Wan, Lunacsek, & 
Sand, 2008). 
 Successful management of IC/PBS is often difficult. Early diagnosis reduces 
patient care costs, as IC/PBS is more responsive to therapy in its early stages (Parsons, 
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2006).  Misdiagnosis, under diagnosis, and delayed diagnosis require patients to seek 
evaluations by multiple health care providers, often leading to unnecessary diagnostic 
testing, surgical procedures and a decreased quality of life (Forrest & Moldwin, 2008; 
Heck, 2007; Sand et al., 2008). The chronic nature of IC/PBS necessitates long-term 
medical management of the disorder and permanent therapeutic regimens to minimize 
symptoms and improve quality of life (Schmid et al., 2011). 
 Wu et al. (2006) conducted a study to estimate the average medical cost for 
patients with IC/PBS in the first year after diagnosis.  These researchers found that the 
average patient spent $1,572 U.S. on medications in the first year of treatment and 
$5,041 during the first year of diagnosis on medical services.  The majority of these costs 
paid for outpatient services (Wu et al., 2006).   Within a year, these IC/PBS patients 
spent approximately $3,320 more than the control group of patients without IC/PBS 
(Wu et al., 2006).  These values only reflect direct cost of medical care for IC/PBS, not 
the cost of lost wages due to an inability to work. Wu et al. (2006) found that the 
indirect cost of IC/PBS in lost wages averages $726 during the first year of diagnosis.    
Quality of life  
 In addition to increased health care cost, women with IC/PBS report a decreased 
quality of life (QOL).  Stanford et al. (2008) found that women with IC reported a 
significantly lower quality of life compared to an average woman. Studies comparing the 
QOL of patients with IC/PBS to women with other chronic diseases found that women 
with IC/PBS reported lower quality of life than women with rheumatoid arthritis, HTN 
and chronic kidney disease on dialysis (Rosamilia, 2005; Rothrock, Lutgendorf, & Kreder, 
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2003).  They reported sleep deprivation and increased levels of pain, including 
dyspareunia.  Moreover, they reported depression, suicidal ideation, absences from 
work, sexual dysfunction, poor family relationships and physical and emotional stress 
(Burkman, 2004; Heck, 2007; Rosamilia, 2005; Stanford et al., 2008).  In short, the 
unpredictable nature of the disease and symptom flares cause debilitating pain, urgency 
and frequency that restrict patients to the restroom, limiting participation in social 
activities (Rothrock et al., 2003; Warren, 2007).  Many women with IC/PBS experienced 
anxiety and depression related to their symptoms, misdiagnosis, delayed treatment, and 
medical costs (Clemens et al., 2010; Forrest & Mishell, 2009; Wu et al., 2006).  Studies 
found that with appropriate disease specific treatment, QOL in women with IC/PBS 
significantly improved (Clemens et al., 2010; Forrest & Mishell, 2009; Sairanen et al., 
2009).  Forrest and Mishell (2009) as well as Sairanen et al. (2009) recommended using 
quality of life indicators to evaluate effectiveness of treatment regimens for IC/PBS.   
 Co-morbidities.  
 Women with IC/PBS often have other co-morbid medical conditions that 
contribute to many of the symptoms that the experience with IC/PBS.  These included 
allergies, fibromyalgia, inflammatory bowel disease, high tone pelvic floor muscle 
dysfunction, endometriosis, vulvodynia, chronic pelvic pain syndrome, UTI, depression 
and anxiety (Hanno, 2002; Panzera, 2007; Parsons, 2006; Wu et al., 2006).  Control of 
co-morbid conditions can improved IC/PBS symptoms.  Parsons (2006) found that over 
seventy percent of patients with IC/PBS also experienced environmental allergies.  One 
theory regarding the etiology of IC/PBS was that damage to the lining of the bladder is 
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related to an allergic response (Burrell & Hurm, 1999).  Control of allergies in women 
with IC/PBS improved IC/PBS symptoms.  Hydroxizine was especially useful over other 
antihistamines because chronic use suppressed degranulation of mast cells (Parsons, 
2006).  A high percentage of women with IC/PBS also experienced depression; treating 
depression in women with IC/PBS with amitriptyline improved depressive symptoms 
and decreased pelvic pain associated with IC/PBS (Hanno et al., 2011; Parsons, 2006; 
Wu et al., 2006).          
 Patient outcomes.  
 IC/PBS is a chronic disease with no known cure; management was targeted at 
relieving symptoms and maximizing quality of life (Dell & Butrick, 2006; Forrest & 
Mishell, 2009; Nickel et al., 2005).  Negative outcomes for women with IC/PBS were 
associated with debilitating pelvic pain and urinary frequency, which progressively 
worsened over time (Panzera, 2007; Rosenberg, Newman, & Page, 2007; Wu et al., 
2006).  The adverse outcomes associated with IC/PBS varied and included sleep 
deprivation, travel and diet restrictions, avoidance of sexual intercourse, sexual 
dysfunction, poor social functioning, decreased mental health, depression, poor family 
relationships and an inability to work (Ibrahim et al., 2007; Panzera, 2007; Rothrock et 
al., 2003; Wu et al., 2006).   
 Many patients faced occupational limitations due to symptoms of IC/PBS 
(Rosenberg, Newman, et al., 2007; Stanford et al., 2008).  Over fifty percent of patients 
with IC/PBS were unable to work full time (Hanno, 2002; Rothrock et al., 2003; Wu et 
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al., 2006).  Ibrahim et al.  (2007) reported that patients with IC/PBS were less likely to 
work full time and more likely to be disabled or unemployed.  
 Women with IC/PBS were more likely to be diagnosed with depression, over half 
of IC/PBS patients reported depression related to urinary symptoms and sexual 
dysfunction (Bogart, Suttorp, Elliott, Clemens, & Berry, 2011; Rosenberg, Newman, et 
al., 2007; Rothrock et al., 2003; Wu et al., 2006).  Women with IC/PBS were less likely to 
seek treatment for their depression due to stigma related to talking about urinary 
disorders and sexual dysfunction caused by symptoms of IC/PBS (Bogart et al., 2011; 
Rosenberg, Newman, et al., 2007; Rothrock et al., 2003).  Sexual dysfunction was 
common among women with IC/PBS, and can took many forms including dyspareunia, 
symptom flares after intercourse, decreased sexual arousal and decreased orgasm 
frequency (Bogart et al., 2011).  Bogart et al. (2011) found that eighty-eight percent of 
women with IC/PBS reported at least one symptom of sexual dysfunction, compared to 
forty-three percent of women in the general U.S. population.  Sexual dysfunction led to 
lack of intimacy and poor family relationships (Bogart et al., 2011; Rosenberg, Newman, 
et al., 2007).  Approximately, seventy percent of IC/PBS patients reported disruption in 
their family relationships and responsibilities due to symptoms of IC/PBS (Rothrock et 
al., 2003; Wu et al., 2006).    
Purpose  
 The purposes of this project was to 1) conduct a substantive literature review on 
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral 
pharmacological interventions and behavioral interventions for IC/PBS, and 3) 
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determine the best practice recommendation for the management of ICS/PBS in adult 
women.        
Management of IC 
 Health care providers were inconsistent in diagnosis and treatment of IC/PBS, 
and many did not recognize the disorder early enough in most patients to effectively 
manage the disease (Forrest & Mishell, 2009; Hanno et al., 2011; Heck, 2007). The 
diagnosis of IC/PBS was difficult due to the lack of specific histopathologic changes, 
unpredictable flares and remissions of symptoms early in the disease progression, and 
an extreme variability in presenting symptoms among patients (Dell, 2007; Hanno, 2002; 
Hanno et al., 2011). It was estimated that the delay in diagnosis from onset of first 
symptoms is between five and seven years (Heck, 2007; Rosamilia, 2005).  Early 
recognition and initiation of appropriate treatment is essential to improved QOL for 
women with IC/PBS.  IC/PBS was shown to respond better to available treatments if 
recognized early.  Many treatments have better therapeutic response if initiated during 
the first two and a half years of symptom onset and response improved over the 
duration of treatment (Forrest & Mishell, 2009; Forrest & Moldwin, 2008; Stanford et 
al., 2008).  Understanding of IC/PBS diagnosis and treatment lead to earlier recognition 
and appropriate treatment and improved outcomes for women with IC/PBS.    
 Currently, there are over 180 different therapies identified to treat IC/PBS, both 
pharmacologic and non-pharmacologic.  However, a gold standard for managing IC/PBS 
is lacking.  Hanno et al. (2011) published the only guideline for the diagnosis and 
management of IC/PBS.  In their guideline, the authors recognized the limitations in the 
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available literature including poorly defined patient groups, small sample sizes, lack of 
placebo controls in many studies, the likely over-estimation of efficacy, short follow-up 
durations, and inconsistency with outcome measure used.  These limitations created 
difficulties in using RCTs for a single meta analysis (Hanno et al., 2011). Hanno et al. 
(2011) made treatment recommendations based on evidence grades B and C, indicating 
that there was weakness in the evidence.  Current treatment of IC/PBS was aimed at 
reducing symptoms to a level acceptable for the individual patient and management 
must be tailored to the individual (Forrest & Moldwin, 2008; Hanno et al., 2011).  
Options included oral medications, intravasicular medications, and behavioral 
interventions including dietary modification and physical therapy (Forrest & Moldwin, 
2008).  Most researchers and experts agreed that a multimodal approach to treating 
IC/PBS combining pharmacologic and non-pharmacologic management strategies, 
starting with least invasive therapies, yielded the best results for women with IC/PBS 
(Burrell & Hurm, 1999; Dell, 2007; Dell & Butrick, 2006; Forrest & Moldwin, 2008; Hanno 
et al., 2011; Klutke & Klutke, 2008).  
 Pharmacologic interventions.   
 Elmiron or pentosan polysulfate (PPS) was the only Food and Drug 
Administration  (FDA) approved medication for the treatment of IC/PBS (Hanno et al., 
2011; Jamison et al., 2007; Klutke & Klutke, 2008; Rosamilia, 2005; Stanford et al., 2008).  
The mechanism of action of PPS was not entirely clear, it is believed that it replaces the 
surface of the GAG layer of the bladder lining and inhibits histamine release by the mast 
cells, decreasing bladder irritation and pain (Klutke & Klutke, 2008; Rosamilia, 2005). 
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Other oral medications that are commonly used “off-label” to treat symptoms of IC/PBS 
included; amitriptyline, antihistamines specifically hydroxazine and cimetidine, 
benzodiazapines and other muscle relaxants, gabapentin, steroids, anticholinergic 
medications, non-steroidal anti-inflammatory drugs (NSAIDs), and narcotic and non-
narcotic pain relievers (Burrell & Hurm, 1999; Hanno et al., 2011; Jamison et al., 2007; 
Stanford et al., 2008).  The intravesical instillation of dimethyl sulfoxide (DMSO) was also 
FDA approved for the treatment of IC/PBS; standard treatment with DMSO was 
considered six doses over a three-month period (Onwude, 2009; Stanford et al., 2008).  
However, DMSO instillations must be done in a clinic setting by a trained professional 
and the effect on symptom relief for IC/PBS patients was not certain (Onwude, 2009).     
 Behavioral interventions.    
 Several non-pharmacological treatments were recommended for the treatment 
of symptoms related to IC/PBS. One of the most common was diet modification, many 
women with IC/PBS reported that symptoms are exacerbated by certain foods it is 
unclear why certain foods seem to worsen symptoms (Dell & Butrick, 2006; Rosamilia, 
2005; Shorter, 2006; Warren, 2007).  Foods that women commonly cited as 
exacerbating IC/PBS symptoms include acidic foods, foods high in potassium, citrus, 
chocolate, caffeine, spices, alcohol, carbonation, tomatoes, vinegar, and artificial 
sweeteners (Dell & Butrick, 2006; Rosamilia, 2005; Shorter, 2006).  Not all foods in this 
list exacerbated symptoms in all women with IC/PBS. Recommendations included that 
women first eliminate all foods and gradually add them back into their diet one at a 
time to identify offensive foods (Warren, 2007).  Other non-pharmacological therapies 
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that were shown to improve symptoms of IC/PBS include stress management, exercise, 
smoking cessation, relaxation techniques, pelvic floor exercises and physical therapy, 
local hot and cold compresses, bladder training, biofeedback, participation in support 
groups, development of coping skills and maintaining social connections (Dell, 2007; Dell 
& Butrick, 2006; Forrest & Mishell, 2009; Hanno et al., 2011; Klutke & Klutke, 2008; 
Rosamilia, 2005; Warren, 2007; Webster & Brennan, 1998).        
PICO Question 
 An extensive review and analysis of literature published from 2002 through 2012 
was conducted to answer the following PICOT question: In women ages 18 and older 
with a diagnosis of IC/PBS, who are not pregnant (P), how do oral pharmacological 
interventions (I) compare with behavioral interventions (C) best practice for managing 
IC/PBS in adult women ages 18 and older, evidenced by a decrease in IC/PBS symptoms 
indicated by a reduction in the patient’s ICSI and ICPI scores from baseline or patient self 
reported improvement of symptoms (T) upon diagnosis? The following table depicts 
that evidence-based practice question in PICOT format.  
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Table 1.1: Evidence Based Practice Clinical Question 
Patient 
Population 
Intervention Comparison 
Intervention 
Outcome Time 
Adult women 
ages 18 and 
older with a 
diagnosis of 
IC/PBS, who are 
not pregnant  
Oral 
pharmacological 
interventions 
Behavioral 
interventions 
Best practice for 
managing IC/PBS in 
adult women ages 18 
and older, evidenced 
by a decrease in 
IC/PBS symptoms 
indicated by a 
reduction in the 
patient’s ICSI and ICPI 
scores from baseline 
or patient self 
reported 
improvement of 
symptoms.   
Upon 
diagnosis  
 
PICO Definitions and Descriptions 
1. Adult women: any female over the age of eighteen.   
2. Behavioral interventions: Modifications that a woman makes to her routine to 
minimize symptoms of IC/PBS including but not limited to diet modification, 
stress reduction, physical therapy, biofeedback and exercises targeted at 
symptom improvement (Dell, 2007; Dell & Butrick, 2006; Forrest & Mishell, 
2009; Hanno et al., 2011; Klutke & Klutke, 2008; Rosamilia, 2005; Warren, 2007; 
Webster & Brennan, 1998). 
3. Best practice: The use of interventions and techniques that are grounded in 
research and known to promote high quality care and patient outcomes (Iowa, 
2012).   
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4. Diagnosis: the use of scientific or clinical methods to establish the cause and 
nature of a person’s illness and functional impairment caused by the pathology 
(Venes, 2005). 
5. Healthcare Provider: refers to advanced practice registered nurses (APRNs), 
physician’s assistants (PA), and physicians that manage the care of women in an 
outpatient setting.   
6. Interstitial Cystitis/Painful Bladder Syndrome: as defined by the Society for 
Urodynamics and Female Urology defines IC/PBS- an unpleasant sensation, 
described as pain pressure or discomfort perceived to be related to the urinary 
bladder and associated with lower urinary tract symptoms of more than six 
weeks duration in the absence of infection or other identifiable cause (Hanno et 
al., 2011).  
7. O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI): a self-administered one-
page assessment of the impact of symptoms of IC/PBS on patient’s QOL.  Scored 
from 0 to 36, a score of 36 representing the most severe symptoms.  Useful in 
the evaluation of effectiveness of treatments for IC/PBS (O'Leary et al., 1998; 
Theoharides, 2007).  
8. O’Leary-Sant Interstitial Cystitis Problem Index (ICPI): a self-administered one-
page questionnaire designed to assess how problematic IC/PBS is for a patient. 
Scored from 0 to 36, a score of 36 representing the most severe symptoms.  
Useful in the evaluation of effectiveness of treatments for IC/PBS (O'Leary et al., 
1998; Theoharides, 2007).  
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9. Patient self-reported symptom reduction: a patient’s response to a particular 
treatment evaluated with an questionnaire that has been developed by 
researchers to evaluate overall improvement in IC/PBS (Anderson & Perry, 2006; 
Sairanen et al., 2005).   
10. Symptom Reduction: A degrease in disuria, urinary frequency and urgency, pelvic 
pain and other symptoms associated with IC/PBS, indicated by a 30% reduction 
in ICSI score from baseline after initiation of treatment (Sand et al., 2008).   
11. Pelvic Pain and Urgency/Frequency (PUF) questionnaire:  a screening tool 
validated for identifying patients in a clinical setting with IC/PBS.  A score of 
twelve or higher is indicative of IC/PBS (Forrest & Mishell, 2009; Rosenberg, 
Page, & Hazzard, 2007).    
12. Pharmacological Interventions: Treatment of IC/PBS symptoms with oral or 
intravesical medication.  Including those FDA approved for treatment of IC/PBS 
and those that have been studied for off label use for treatment IC/PBS (Dell & 
Butrick, 2006; Hanno et al., 2011). 
13. Symptoms of IC/PBS: urinary urgency, frequency, bladder pain, chronic pelvic 
pain, bladder pain, nocturia, dysuria and dyspareunia (Chaiken et al., 1993; Dell, 
2007; Hanno et al., 2011; Heck, 2007).   
Summary 
 IC/PBS is a chronic health condition that predominantly affects adult women. 
Though the exact prevalence of the disorder is unknown, it was found to affect a 
significant portion of the population (Forrest & Moldwin, 2008; Ibrahim et al., 2007; 
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Rosenberg & Hazzard, 2005). IC/PBS was difficult to diagnose and treat because of its 
variable symptom presentation, a lack of universally accepted diagnostic criteria, and 
unfamiliarity with IC/PBS by health care providers (Forrest & Mishell, 2009; Klutke & 
Klutke, 2008; Patel et al., 2008). The abundance of treatment options and a lack of 
standardized treatment guidelines make determining the best course of treatment 
challenging for healthcare providers.   
 The purposes of this project was to 1) conduct a substantive literature review on 
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral 
pharmacological interventions and behavioral interventions for IC/PBS, and 3) 
determine the best practice recommendation for the reduction of IC/PBS symptoms in 
women, ages 18 and older.        
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CHAPTER 2 
ANALYSIS OF THE LITERATURE 
Introduction 
 The purposes of this project was to: 1) conduct a substantive literature review on 
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral 
pharmacological interventions and behavioral interventions for IC/PBS, and 3) 
determine the best practice recommendation for the management of ICS/PBS in adult 
women, ages 18 and older.  Chapter 2 provides an overview of the database findings, a 
review of the literature available on oral pharmacological interventions for IC/PBS and 
behavioral interventions for IC/PBS, and an overview of the American Urological 
Association (AUA) Guideline on diagnosis and treatment of IC/PBS.          
Overview  
 An extensive search of current literature was conducted to answer the PICO 
question; “in adult women ages 18 and older with a diagnosis of IC/PBS who are not 
pregnant, how do oral pharmacological interventions compare with behavioral 
interventions as best practice for managing IC/PBS in women over 18 upon diagnosis?”  
Initially a search was conducted for pre-appraised synthesized resources through 
databases such as the Cochrane database of systematic reviews, the Joanna Briggs 
institute, the National Guideline Clearing House and Annual Reviews (Melnyk & Fineout-
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Overholt, 2011; Sairanen et al., 2009; Sairanen et al., 2005)).  Unfortunately, a search of 
these databases yielded few useful results. One guideline on the diagnosis and 
treatment of IC/PBS published by the American Urological Association Education and 
Research Inc. was found. The majority of research completed on IC/PBS was in the form 
of peer-reviewed journal articles and research studies.     
 The search was broadened to include a thorough search of available 
bibliographic databases (Melnyk and Fineout-Overholt, 2011).  Bibliographic databases 
searched were CINHAL, Medline (OVID), PubMed-Medline, Web of Science, CSA, Health 
Source: Nursing/Academic edition, Nursing Resource Center, Essential Evidence Plus, 
Dissertations and Theses, and Annual Reviews (Melnyk & Fineout-Overholt, 2011). A 
summary of the search results is provided in table 2.1.  
 In conducting the search of the literature the following search terms were used, 
“interstitial cystitis”, “interstitial cystitis and management”, “interstitial cystitis and 
management and adult women”, “interstitial cystitis and oral management”, interstitial 
cystitis and behavior management”, “interstitial cystitis and treatment”, “interstitial 
cystitis and treatment and adult women”, “interstitial cystitis and oral treatment”, 
“interstitial cystitis and behavior treatment”.  Searches included searches of titles, 
keywords, and abstracts.    
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Table 2.1 Database Findings 
Database Key Words Results 
Cochrane Library Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
 
Interstitial cystitis and 
treatment 
 
 
Interstitial cystitis and oral 
treatment  
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
3 
 
1 
 
 
1 
 
 
0 
 
 
1 
 
 
 
2 
 
 
 
2 
 
 
0 
 
 
1 
Joanna Briggs Institute Interstitial cystitis 0 
National Guideline Clearing 
House 
Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
9 
 
8 
 
 
6 
 
 
3 
 
 
6 
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Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment   
 
Interstitial cystitis and 
treatment and adult women 
9 
 
 
6 
 
 
3 
 
 
6 
 
CINHAL Plus with Full Text Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
443 
 
46 
 
 
1 
 
 
1 
 
 
0 
 
 
126 
 
 
5 
 
 
0 
 
 
1 
Medline (OVID) Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
5294 
 
1270 
 
 
0 
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Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
 
Interstitial cystitis and adult 
women and behavior 
treatment 
 
Interstitial cystitis and oral 
treatment and adult women  
 
2 
 
 
47 
 
 
3306 
 
 
888 
 
 
281 
 
 
68 
 
 
16 
 
 
 
35 
PubMed-Medline (with USC 
links) 
Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
2427 
 
251 
 
 
34 
 
 
16 
 
 
47 
 
 
 
1551 
 
 
156 
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Interstitial cystitis and oral 
treatment and adult women 
 
Interstitial cystitis and 
behavior treatment and adult 
women 
 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
21 
 
 
 
15 
 
 
 
66 
 
 
192 
Web of Science Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
1985 
 
0 
 
 
741 
 
 
66 
 
 
17 
 
 
15 
Health Source: 
Nursing/Academic Edition 
Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
 
Interstitial cystitis and 
219 
 
35 
 
 
0 
 
 
0 
 
 
0 
 
 
 
99 
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treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
 
4 
 
 
4 
 
 
0 
Nursing Resource Center Interstitial cystitis 2 
Essential Evidence Plus Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
29 
 
16 
 
 
11 
 
 
8 
 
 
5 
 
 
25 
 
 
13 
 
 
8 
 
 
7 
Dissertations and Theses Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
287 
 
208 
 
 
127 
 
 
156 
 
  29 
 
Interstitial cystitis and 
management and adult 
women 
 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
 
153 
 
 
 
276 
 
 
160 
 
 
195 
 
 
178 
Annual Reviews Interstitial cystitis 
 
Interstitial cystitis and 
management 
 
Interstitial cystitis and oral 
management 
 
Interstitial cystitis and 
behavior management 
 
Interstitial cystitis and 
management and adult 
women 
 
Interstitial cystitis and 
treatment 
 
Interstitial cystitis and oral 
treatment 
 
Interstitial cystitis and 
behavior treatment  
 
Interstitial cystitis and 
treatment and adult women 
22 
 
10 
 
 
5 
 
 
4 
 
 
0 
 
 
5 
 
 
0 
 
 
0 
 
 
0 
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 Articles were included if they were published after 2002 to ensure that recent 
literature and a sufficient quantity of quality studies was used to answer the PICOT 
question; with the exception of one study that is the foundation of behavioral 
interventions for IC/PBS.  All articles included in this review were limited to those 
published in English; however, articles from countries other than the United States were 
included as long as they were available in English.  Articles were limited to those that 
addressed the care of adults, as the population that the PICOT question sought to 
address was adult women.  Articles that exclusively pertained to IC/PBS in men were 
excluded because the PICOT question specifically addresses the management of IC/PBS 
in women.  However, studies that included both men and women could not be 
excluded, as some of the findings from these studies are pertinent to the management 
of IC/PBS in women. Twenty-seven articles were included in this analysis, a summary of 
each of these articles can be found in the table in Appendix A.  
Appraisal of the Evidence  
 The first priority in selecting articles was to choose articles with a high grade of 
evidence and whose content most specifically addressed the PICOT question.  When 
choosing which articles to evaluate the hierarchy of evidence that was used to select 
articles for inclusion and to evaluate those articles was the levels of evidence presented 
by the Scottish Intercollegiate Guidelines Network (2011) in the guide SIGN 50, a 
reproduction of this hierarchy for grading evidence is included in Appendix B.  The SIGN 
guide has 8 grades of evidence.  Grades are as follows from lowest level of evidence to 
highest: 4 expert opinions, non-systematic reviews of literature and clinical articles; 3 
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non-analytical studies; 2- case control or cohort studies with high risk of bias; 2+ well 
conducted case control or cohort studies with low risk of bias; 2++ high quality 
systematic reviews of case control or cohort studies; 1- meta-analysis, systematic 
reviews, or randomized control trials (RCTs) with high risk of bias; 1+ well conducted 
meta analysis, systematic reviews or RCTs with low risk of bias; 1++ high quality meta 
analysis, systematic reviews of RCTs or RCTs with very  low risk of bias (SIGN, 2011).  The 
grade assigned to each piece of evidence is listed in the second column of the table in 
Appendix A.   
 The American Urological Association (AUA) Guidelines for the Diagnosis of and 
Treatment of Interstitial Cystitis/Bladder Pain Syndrome by Hanno et al. (2011) was 
analyzed as part of this review.  The Appraisal of Guidelines Research and Evaluation 
(AGREE) instrument was used in the analysis of this guideline.  The AGREE instrument 
was used following these instructions, (AGREE, 2011) written by the AGREE 
Collaboration published in their 2001 guide. Utilizing this instrument this author rated 
the guideline on its performance in the following six categories: scope and purpose, 
stakeholder involvement, rigor of development, clarity and presentation, applicability, 
and editorial independence (AGREE Collaboration, 2001).  Overall the AUA guideline 
received a 71%, details of the scoring in each categories are listed in the table in 
Appendix A.  The major weaknesses of this guideline are inherent to the lack of available 
scientific research to support the guideline and the disease process of IC/PBS.  The 
medical community wrote the guideline for patients and healthcare providers based on 
anecdotal evidence from experts caring for patients with IC/PBS.  The authors also did 
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not address the cost of treatments or consider input from patients with IC/PBS.  There is 
also no plan for how the guidelines will be updated as new research becomes available 
(Hanno et al. 2011).    
Oral Pharmacological Interventions 
 Twelve articles addressed the use of oral pharmacological interventions for the 
management of IC/PBS in adult women.  Seven of these articles reviewed the use of 
pentosan polysulfate (PPS) or Elmiron; the other five articles examined the use of other 
oral medications to manage symptoms of IC/PBS including amitriptyline, 
anticholinergics, oral contraceptives, muscle relaxants, and antihistamines.  
 Pentosan polysulfate.  
 Pentosan polysulfate (PPS) is a semi-synthetic sulfated polysaccharide that is 
chemically similar to heparin, it was the only oral medication approved by the FDA for 
treatment of IC/PBS (Anderson & Perry, 2006).  The exact pharmacokinetics were not 
understood well.  However, it was documented that PPS repairs the glycosaminoglycan 
(GAG) layer of the bladder epithelium reducing permeability to toxins (Anderson & 
Perry, 2006).  Eight articles that examined the use of PPS for management of IC/PBS 
were reviewed; the majority demonstrated the highest levels of evidence (rated 1+ by 
the SIGN guide) available on the management of IC/PBS.  
 Nickel et al. (2005) conducted a RCT on the uses of PPS for the management of 
adults with IC/PBS.  In a double-blind analysis of 380 adult women with IC/PBS, Nickel et 
al. (2005) examined the effect of three dosages of PPS, 300mg daily, 600 mg daily, and 
900mg daily.  Results showed no statistically significant differences in the responses 
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among the three treatment groups for dosage, but 17 to 23 percent of participants 
reported relief after four weeks on PPS therapy.  At the end of the thirty-two week 
study, another 59 to 67 percent of the participants had statistically significant 
improvement in IC/PBS symptoms even if they did not have improvement at the four-
week measurement, regardless of the dose of PPS (p < .05) (Nickel et al., 2005). A 
significant limitation of this study is that there was not a placebo comparison group; all 
participants were in a treatment group that received PPS in varying doses (Nickel et al., 
2005).   
 A RCT conducted by Sairanen et al. (2005) compared treatment of IC/PBS 
symptoms with PPS and oral Cyclosporine A.  This trial found that Cyclosporine A was 
significantly more effective (p<0.001) at reducing micturition frequency by fifty percent 
than PPS after 6 months of treatment (Sairanen et al., 2005).   However, adverse events 
were more common in the Cyclosporine A treatment group; 30 out of 94 patients 
experienced adverse events including increased blood pressure and increased serum 
creatinine.  Adverse events with PPS were less common and less severe; the most 
common adverse events were gastrointestinal upset, fatigue and headache (Sairanen et 
al., 2005).  The authors cautioned that though effective, patients treated with 
Cyclosporine A for IC/PBS should be monitored closely, including regular monitoring of 
blood pressure and serum creatinine measurements for renal function (Sairanen et al., 
2005).   
Sairanen et al. used data from the 2005 study in a subsequent 2009 study to 
compare the effects of IC/PBS treatments on quality of life.  The purpose of this study 
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was to evaluate the treatment effect on the quality of life (QOL) of patients with IC/PBS.  
Authors surmised QOL is compromised in these patients due to the nature of the 
chronic disease.   There is not an established specific questionnaire for evaluating QOL 
in patients with IC/PBS.  However, the authors used a 30-item questionnaire developed 
and validated by Cleary et al. (1995) for evaluation of QOL in patients with prostate 
carcinoma (Sairanen et al., 2009).  This questionnaire was a self-administered 
questionnaire that evaluated the QOL categories of general health perceptions, pain, 
emotional well-being, vitality, social functioning, physical capacity, and sexual interest 
and functioning (Cleary, Morrissey, & Oster, 1995).  A sample of 550 patients with 
metastatic prostate cancer was used to validate this questionnaire. Cleary et al. (1995) 
found that the estimated reliability coefficient (alpha) for the scales in each country 
studied ranged from 0.82 to 0.96, with the exception of items concerning sexual interest 
and functioning (alpha >0.74).  Correlations between general health perception and 
other QOL measures were used to determine construct validity.  In all subscales, except 
sexual interest and functioning, the correlation was greater than 0.30 in the predicted 
direction (Cleary et al., 1995).  Limitations exist in the reliability and validity of this 
questionnaire when evaluating sexual aspects of QOL.  Siranen et al. (2009) used this 
questionnaire with the exclusion of a question addressing the issue of erectile 
dysfunction because 89% of the study population was women.  The scores between the 
QOL categories were compared using the Wilcoxon sum test and a one-way ANOVA was 
applied to calculate the similarity of baseline characteristics between all treatment 
arms. There were no documented statistically significant differences in baseline 
  35 
characteristics between the Cyclosporine A and PPS groups (Sairanen et al., 2009).  Both 
the Cyclosporine A and PPS treatment groups saw improvement in QOL scores.  
However, the Cyclosporine A therapy had a statistically significantly higher quality of life 
response score than PPS therapy (p <0.001).   Limitations of this study existed due to 
unresearched modifications of the QOL instrument and its use in this study.  Because a 
QOL tool for the evaluation of patients with IC/PBS did not exist, the authors use a tool 
validated for another disease.  That this tool has the same reliability and validity for 
evaluating QOL in patients with IC/PBS cannot be assumed.  Another limitation or 
concern was the use of Cyclosporine A in treatment of IC/PBS.  This form of treatment 
was under review and not FDA approved for the management of IC/PBS.  Investigators 
claimed that further studies need to be conducted to support the findings of this RCT by 
Sairanen et al. (2009) before recommending the use of Cyclosporine A for management 
of IC/PBS.  This Finnish study concluded that while Cyclosporine A is more effective than 
PPS, side effects were more common and patients must be monitored more closely 
when taking Cyclosporin A, than when taking PPS (Sairanen et al., 2005).  
 In a secondary analysis of the RCT by Nickel et al. (2005), Nickel et al. (2008) 
determined that initiation of PPS therapy within six months of diagnosis with IC/PBS 
demonstrated statistically significantly improved patient outcomes as measured by 
improvement in the IC symptom index (ICSI) and IC problem index (ICPI) compared to 
patients who did not receive PPS until two years or more after diagnosis. The ICSI and 
ICPI are each a four question self-administered questionnaire that is scored using a 
Likert Scale 1-5.  The ICSI is designed to capture the most important voiding and pain 
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symptoms and The ICPI is designed to assess how problematic patients find these 
symptoms in a clear and concise manner, (O'Leary, 1997).  These two indices were 
initially validated in a study that compared responses from 45 patients diagnosed with 
IC/PBS and 67 volunteers who denied any voiding symptoms.  Demographic 
characteristics of the two groups were not significantly different, with the exception 
that control subjects were more likely to have higher levels of education (O'Leary et al., 
1997).  Internal consistency (Cronbach’s alpha) for the ICSI exceeded 0.85, and 0.90 for 
the ICPI.  Test-retest reliability exceeded 0.90 for both indices.  Construct validity was 
measured through correlations with two overall measures of significance of symptoms.  
All but one of the correlations was statistically significant.  The authors concluded that 
the symptom scores for the controls had very little variance (O'Leary et al., 1997).  The 
ICIS and ICIP used together captured the significance of the problem from the patient’s 
perspective.  The indices were not intended to be used as screening tools, rather as an 
adjunct in the diagnosis and in evaluation of management of patients with IC/PBS 
(O'Leary et al., 1997).  Nickel et al.  (2008) performed a retrospective sub-analysis of 128 
subjects from the previous RCT who received 300 mg a day of PPS.  Subjects were 
categorized into two groups as receiving early treatment or late treatment.  Early 
treatment was defined as treatment within 6 months of the diagnosis of IC and late 
treatment was defined as treatment initiation 24 months after diagnosis with IC (Nickel 
et al., 2008).  An ANCOVA covariance model, including a category for time since IC 
diagnosis to PPS initiation as a factor and baseline score as a covariate , was used to 
compare ICSI and ICPI scores between the two treatment groups (Nickel et al., 2008).   
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ICSI mean scores in the early treatment group improved by an average of 3.97 points 
compared to an improvement of 2.15 points in the late treatment group (p < 0.05).  ICPI 
mean scores improved an average 3.94 points in the early treatment group and only 
1.77 points in the late treatment group (p < .01).  Authors concluded that patients with 
IC/PBS benefit from earlier initiation of PPS therapy (Nickel et al., 2008).  Limitations of 
this study included the use of time from diagnosis to initiation of PPS to evaluate time 
until initiation of treatment. This may not be representative of the duration of IC/PBS 
symptoms, since many patients with IC/PBS suffer with symptoms for months to years 
before diagnosis.  Both the early and late treatment groups had moderate to severe 
IC/PBS symptoms at baseline making it difficult to generalize findings to include patients 
experiencing mild IC/PBS symptoms.  The majority of patients had also received at least 
one medication for IC/PBS before enrollment in the study.  This may have created an 
unknown bias (Nickel et al., 2008).  
 Sand et al. (2008) also performed a secondary analysis of the RCT conducted by 
Nickel et al. (2005).   Sand et al. (2008) analyzed a subset of 128 women who received 
300mg of PPS a day to determine response to treatment.  Women were labeled 
responders to PPS therapy if a 30% reduction in ICIS score was seen at the end of the 32 
week study (Sand et al., 2008).  Forty-two percent of women were identified as 
responders to PPS treatment.  However, 70% of women studied reported that they 
experienced a benefit from PPS therapy, and that relief with PPS was greater than any 
treatment that they had previously tried (Sand et al., 2008). The majority of subjects 
(91%) were women, 95% of these women were considered to have moderate to severe 
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baseline IC symptoms.  Using the criteria of a reduction of 30% or more in ICSI scores to 
define patients as responders, 42% (49 patients) responded to PPS (Sand et al., 2008).  
PPS treatment responders were statistically significantly more likely to have higher 
ratings on the treatment satisfaction questionnaire than non-responders (p < 0.001).  
Fisher’s exact two sided test and Odds ratio analysis found responders were 6.27 times 
more likely to be pleased with PPS (p < 0.001), 6.17 times more likely to benefit from 
PPS for IC/PBS symptoms (p < 0.001) and 2.73 times more likely to recommend PPS for 
IC/PBS symptoms (p < 0.005) (Sand et al., 2008).  Seventy-nine percent of responders 
reported that PPS provided better relief than previous treatments (p < 0.005).   Among 
all subjects, 70% reported a benefit from PPS at the end of the treatment period, even if 
they were not identified as responders (Sand et al., 2008).  The limitations of this study 
were related to the sample extracted from the original RCT.  The sub-sample from the 
original RCT analyzed in this study was relatively small (n=128). The majority of subjects 
(91%) were women with moderate to severe IC/PBS symptoms at baseline, making it 
difficult to generalize this data to a population of IC/PBS patients with mild symptoms 
(Sand et al., 2008).   
 Dimitrakov et al. (2007) conducted a systematic review of RCTs for 
pharmacologic treatment of patients with IC/PBS.  The authors included 21 RCTs that 
were published between 1987 and 2006 that met inclusion criteria.  Articles were 
excluded if they did not address treatment of IC/PBS or report global or symptom-
specific outcomes, did not use RCT double blind placebo controlled design, include 
patients without a diagnosis of IC/PBS, were incomplete or duplicate publications, were 
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not in English, or had a sample size of less than 10 (Dimitrakov et al., 2007).  A total of 
1470 adults participated in the 21 RCTs; 90% of these were women (Dimitrakov et al., 
2007).  Global and individual symptom improvement was reported in all of the studies 
reviewed, global improvement was viewed as the common outcome across all 
treatments and was usually reported as the number of patients reporting self-
improvement in each group (Dimitrakov et al., 2007).  The average frequency of global 
improvement was 19% among control groups and 49% among treatment groups for all 
RCTs. Only trials for treatment of IC/PBS with PPS had sufficient numbers to allow a 
pooled analysis of effect using a random-effects model (Dimitrakov et al., 2007).  Six 
RCTs and one meta-analysis addressed treatment with PPS, the pooled analysis by 
Dimitrakov et al. (2007) suggested a benefit from treatment (p < .05).  
 In a review of research literature on PPS for treatment of IC/PBS, Anderson and 
Perry (2006) found that PPS had a beneficial effect for a large portion of patients with 
IC/PBS. Anderson and Perry (2006) conducted a search of medical literature published in 
any language from 1980 to 2006.  Studies were captured if they included patients 
diagnosed with IC/PBS who received PPS.  When available large, well controlled trials 
with appropriate statistical methodology were preferred, however relevant 
pharmacodynamic and pharmacokinetic data were also included (Anderson & Perry, 
2006).    According to Anderson and Perry (2006), the evidence supported the use of PPS 
for management of IC/PBS.  PPS was generally well tolerated, easy to use over invasive 
medications, and demonstrated statistical significance in reducing pain over time. 
Research showed that it is a more convenient treatment option than other FDA 
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approved intravesical medications, such as DMSO that required clinical visits and were 
time consuming and painful (Anderson & Perry, 2006).   They also found that data from 
non-comparative studies showed that PPS was effective over a 116-month period.  
Patients should be advised that it may take 3 to 6 months to see full treatment effect, 
and treatment may need to be continued indefinitely to maintain effect.  However, 
patients who have not seen efficacy of PPS in a treatment period greater than 6 months 
were not likely to show statistically significant improvement in pain with PPS (Anderson 
& Perry, 2006).  Anderson and Perry (2006) concluded that PPS was beneficial for 
improvement of overall condition and relief of pain for patients with IC/PBS but that the 
degree of improvement varied among patients.  
 Two articles based on expert opinion by Parsons (2002 & 2006) stated that the 
use of PPS was successful in the treatment of IC/PBS, but duration of treatment was 
more important than dosage, Parsons also found younger patients 10 to 30 years old 
had good symptom improvement over a 2 to 4 month period.  Parsons (2006) noted 
that PPS improved symptoms of IC/PBS by correcting the dysfunction of the GAG 
bladder lining.  The author noted that studies did not explore the added benefit of 
treating IC/PBS with PPS in conjunction with other oral medications (Parsons, 2006).  
Therefore, Parsons (2006) suggested that optimal management of IC/PBS was through a 
multimodal approach that included the use of PPS.   
 Other oral medications.  
 Other medications used in the management of IC/PBS included antihistamines, 
tricyclic-antidepressants (TCAs) such as amitriptyline, anticholinergics, and skeletal 
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muscle relaxants (Dell & Butrick, 2006).  Five articles examined the use of oral 
pharmacological agents other than PPS for the management of IC/PBS.   
In their systematic review of 21 RCTs for management of IC/PBS, Dimitrakov et 
al. (2007) found that amitriptyline is effective therapy of IC/PBS (p < 0.05).  However, 
hydroxysine did not show a significant effect on symptom reduction (p >0.05).  One RCT 
on the use of amitriptyline to treat IC/PBS found that 15 of 24 patients had symptomatic 
relief with an average dose of 75 mg daily.  However, the study did not provide details 
regarding the use of active or inactive placebo between groups (p < .05) (Dimitrakov et 
al., 2007).  Many RCTs had short duration study times, did not account for the variability 
of IC/PBS symptoms over time, had inadequate blinding, small sample sizes (less than 
30), or non-standardized evaluation outcomes making the determination of optimal 
treatment difficult between studies.  The authors concluded, based on the limitations in 
the trials, that other than for PPS, there was insufficient evidence to recommend the 
use of other pharmacological therapies (Dimitrakov et al., 2007).  Moreover, they 
concluded that thus far, trials for treatment of IC/PBS with PPS had sufficient sample 
numbers to allow a pooled analysis of effect using a random-effects mode.  For the 
remaining treatment modalities, a pooled analysis was not attempted due to a wide 
variety of designs and small sample sizes.  The authors attempted to abstract data as a 
standardized mean difference to produce measure of effect for each treatment trial on 
a similar metric, however it was not possible to classify results as positive or negative 
outcome in terms of efficacy (Dimitrakov et al., 2007).   
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A cross-sectional study of 750 patients with IC/PBS investigated the medications 
pH modulator Prelief, phenazopyridine and PPS use for improved symptoms (Hill, Isom-
Batz, Panagopoulos, Zakariasen, & Kavaler, 2008).  Hill et al. (2008) surveyed patients via 
a computer based Internet survey that was linked on the Interstitial Cystitis network, 
national Women’s Health Network and Our Bodies Ourselves websites.  Questions 
included demographic data, and specific information about procedures and mediations 
used to treat IC/PBS and whether patients perceived their condition as improved, not 
affected, or deteriorated after treatment (Hill et al., 2008).  Statistical analyses were 
conducted (chi-squared tests) to compare the perceptions of each treatment group 
(three treatment groups) for outcomes: improved, no effect or worse (Hill et al., 2008).  
Statistically significant improvements were reported among groups for all drugs 
examined (p < 0.001).  Of the 52.7%  (n = 395, N = 750) of individuals who were 
prescribed PPS, 53.4% found that the medication improved IC/PBS symptoms, 3.8% 
reported worse symptoms, and 29.9% reported no effect.  Thirteen percent of patients 
reported intolerable side effects with PPS (p < 0.001) (Hill et al., 2008).  Other 
medications that significantly improved patients’ IC/PBS symptoms include 
phenazopyridine, calcium glycerophosphate (Prelief), amitriptyline, and codeine.  
Vistaril, tolterodine, oxybutynin, oxybutyninXL, and diphenhydramine were reported to 
have no effect on IC/PBS symptoms (p > .05) (Hill et al., 2008).  Patients also found that 
oral medications were better than invasive therapy for management of IC/PBS 
symptoms (Hill et al., 2008).   
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Schmid et al. (2011) conducted a prospective cohort study of women diagnosed 
with IC/PBS to determine if their treatment algorithm based on current literature 
affected sexual function, quality of life and symptoms in women with IC/PBS.   Seventy-
two patients diagnosed with IC/PBS based on the National Institute for Diabetes and 
Digestive and Kidney Diseases (NIDDK) criteria completed the study.  The NIDDK 
developed criteria for clinical trials to ensure that patient populations were similar, the 
criteria were strict, and included changes seen on cystoscopy as a criteria for diagnosis 
(Hanno, 2002).  Figure 2.1 shows the complete list of the NIDDK criteria for the diagnosis 
of IC/PBS.  The treatment algorithm used by Schmid et al. (2011) followed a stepwise 
approach to the treatment of IC/PBS starting with oral tetracycline, progressing to 
bladder instillations, and eventually neurostimulation if symptoms did not improve. 
Quality of life was assessed by the King’s Health Questionnaire, a visual analogue scale 
(VAS) that assessed symptom severity (Schmid et al., 2011).  The King’s Health 
Questionnaire was a questionnaire that determined various aspects of quality of life 
such as sleep, symptom bother, physical limitations, role limitations and emotions.  This 
21 question self-administered questionnaire was designed and validated to assess 
condition-specific quality of life of women with urinary incontinence (Kelleher, Cardozo, 
Khullar, & Salvatore, 1997).  The questionnaire was administered to 293 women prior to 
the date of a scheduled urodynamic study, to evaluate reliability.  The women were 
then asked to complete the questionnaire again after the completion of these studies. 
Cronbach’s alpha was greater than 0.7 in all domains of the questionnaire (Kelleher et 
al., 1997).   One hundred and ninety-three women who completed the King’s Health 
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Questionnaire also completed the Short Form 36 questionnaire, which was validated as 
a tool for measuring quality of life.  A statistically significant  (p < 0.01) correlation 
existed between scores on the King’s Health Question and the Short Form 36 in all 
domains evaluated by the Short Form 36, some domains on King’s Health Questionnaire 
specifically relating to urinary symptoms are not evaluated by the Short Form 36 
(Kelleher et al., 1997).  A visual analogue scale (VAS) was used by Schmid et al. (2011) to 
quantify the severity of symptoms.  Women were asked to name their most bothersome 
symptoms and apply a rating of 0 to 10 using the VAS; 0 being the least bother and 10 
the worst possible bother of bladder symptoms.  The authors did not elaborate on the 
reliability and validity findings of the scale when used for evaluating the severity of 
bladder symptom bother.  A two-tailed t test compared mean scores before and after 
treatment (Schmid et al., 2011).  Researchers found that a stepwise approach to 
management of symptoms with tetracycline, oral steroids, and antihistamines 
significantly improved sexual function and quality of life in women with IC/PBS.  VAS 
scores for pain improved significantly after receiving treatment (p < 0.001), as did 
nocturia (p < 0.01) and urinary frequency (p < 0.01) (Schmid et al., 2011).  However, 
urgency was not statistically significantly improved using this treatment algorithm (p > 
0.09).  All domains of the King’s Health Questionnaire showed significant improvement 
(p < 0.001) with the exception of incontinence impact (p > 0.227) (Schmid et al., 2011).  
Weaknesses of this study included the use of a VAS that was not clearly defined and not 
validated for measurement of pain or symptom bother in this patient population.  Study 
results may not be able to be applied to a general IC/PBS population due to the 
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restrictive nature of the NIDDK diagnostic criteria. In addition, using patients who had 
histories of failures with other treatments might suggest that these patients may have 
had more severe symptoms than the general population of IC/PBS patients.       
 Two reviews of available medical literature examined the use of oral medications 
for the management of IC/PBS.  Unwin (2011), in a review of current evidence for 
Essential Evidence, concluded that treatment of IC/PBS with PPS, amitriptyline and 
bladder instillation with DSMO are the cornerstones of treatment.  This 
recommendation was supported by level B evidence indicating that further research is 
needed and that the evidence is inconsistent or of poor quality (Unwin, 2011).   The 
strongest evidence (level A), well conducted controlled studies, supported the use of 
amitriptyline for the treatment of pain, urgency and frequency associated with IC/PBS.  
Amitriptyline was considered safe and effective and best used in conjunction with PPS 
and non-pharmacologic management such as bladder training, diet, counseling and 
physical therapy (Unwin, 2011).   In an analysis of available literature on the treatment 
of IC/PBS Onwude (2009) found that there were no standardized treatment 
recommendations for IC/PBS and that current RCTs offered conflicting results.  The 
author recommended that clinicians and patients understand that evidence on 
treatment of IC/PBS is limited and that they set realistic goals for management 
(Onwude, 2009).   
 Summary.  
 The most rigorous studies examined the use of PPS for treatment of IC/PBS.  
Current evidence supported the use of PPS for the treatment of IC/PBS.  PPS is the only 
  46 
medication that is FDA approved for treatment of IC/PBS, and is generally well tolerated 
(Anderson & Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; 
Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008).  The recommended dose 
of PPS is 300mg daily divided into three 100mg doses.  Nickel et al. (2005) found that 
longer duration of treatment led to better outcomes.  In a subsequent study, Nickel et 
al. (2009) found that early initiation of treatment also improved patient outcomes.  Sand 
et al. (2008) used data from the RCT conducted by Nickel et al. (2005) and found that in 
the majority of patients PPS was more effective than other therapies.   In a pooled 
analysis of 6 RCTs, Dimetrakov et al. (2007) found data to support the use of PPS in 
management of IC/PBS.   
Other oral medications assisted with the symptoms of IC/PBS.  Sairanen et al. 
(2005) found that Cyclosporine A was more effective at relieving symptoms of IC/PBS, 
however the side effects associated with Cyclosporine A were significantly higher than 
those associated with PPS.  Other medications including phenazopyridine, calcium 
glycerophosphate (Prelief), amitriptyline, and codeine were shown to help relieve 
symptoms of IC/PBS taken in adjunct with PPS (Hill et al., 2008; Unwin, 2011).  While 
there is lower level evidence that phenazopyridine, Prelief, amitriptyline, and codeine 
are effective in relieving symptoms of IC/PBS, RCTs are needed to be conducted to 
demonstrate efficacy, especially for off label use for the management of IC/PBS.   
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Figure 2.1: NIDDK Diagnostic Criteria from Hanno (2002) 
 
 
Behavioral Interventions 
 A dearth of literature exists examining the effectiveness of behavioral 
interventions beyond case reports, anecdotal reports, and expert opinions. Chaike, 
Blaivas, and Blaivas (1993) conducted a case study of 42 women with persistent 
symptoms of urinary frequency and pain that increased in intensity when voiding was 
delayed and was produced by bladder filling (Chaiken et al., 1993).  This study examined 
the effect of behavioral therapy on urgency, frequency and pain related to IC/PBS.  All of 
the women in this study had tried other treatments for IC/PBS including antibiotics, 
tricyclic antidepressants, muscle relaxers, anticholinergics, sedatives, intravesical 
instillations and mechanical interventions such as urethral dilation and hydrodistention.  
Patients noted temporary improvement from these therapies but no long-term relief 
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(Chaiken et al., 1993).  In their study, participants attended one 45-minute behavioral 
therapy session per week for 8 to 12 weeks.  An experienced therapist with training in 
psychology and lower urinary tract physiology performed therapy (Chaiken et al., 1993).  
Baseline values for total daytime void volumes, maximum voided volume, mean voided 
volume, maximum and mean inter-voiding intervals and total number of micturitions 
was recorded. Post treatment values in the same categories were determined and 
patients were asked to rate their global results of therapy as markedly improved, 
improved, unimproved or worse.  Baseline and post treatment mean values for void 
volumes, maximum voided volume, mean voided volume, maximum and mean inter-
voiding intervals, and total number of micturitions were compared using a t-test 
(Chaiken et al., 1993).  Over half of the women who participated reported that their 
symptoms were improved and the average increase in interval between voids was 123 
minutes (Chaiken et al., 1993).  The functional bladder capacity increased in 38 of 42 
patients (p < 0.01), inter-voiding interval increased in all patients by an average of 93 
minutes (p < 0.01), the maximum interval increased in 38 of 42 patients (p < 0.01) and 
41 patients experienced a decrease in the number of micturitions a day by an average of 
9 (p<0.01) (Chaiken et al., 1993).  The authors concluded that behavioral therapy was 
effective in reducing symptoms associated with IC/PBS.  However, therapy required a 
highly motivated patient and access to a skilled therapist in order to be successful 
(Chaiken et al., 1993).  This study was the most rigorous scientific study to date 
evaluating the effect of behavior modification of symptoms of IC/PBS.  This rigor 
justified its inclusion for this review, despite the date of publication.   
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Chaiken et al. (1993) studied women who had failed treatment of IC/PBS with 
antibiotics, tricyclic antidepressants, muscle relaxers, anticholinergics, sedatives, 
intravesical instillations and mechanical interventions such as urethral dilation and 
hydrodistention.  Some of these treatments are still used for IC/PBS.  However since the 
publication of Chaiken et al.’s study, new treatments have become available, such as 
PPS.  Currently, there have not been well-controlled trials comparing behavioral 
modification such as those examined by Chaiken et al. (1993) to current 
pharmacological therapy available for IC/PBS, such as PPS.  An additional weakness was 
that results from this study were not able to be generalized to all women with IC/PBS. 
Women included in this study completed a detailed voiding journal; 16 participants 
were excluded from the results because of a failure to keep the voiding journal.  
Behavioral therapy requires highly motivated patients and skilled therapist.  Women 
included in this study were motivated to meet all participation requirements, yet future 
IC/PBS patients may not have the motivation or resources to successfully complete 
behavioral therapy.  
 Researchers identified stress reduction as an important component of 
management of IC/PBS.  Increased stress levels appeared to exacerbate IC/PBS 
symptoms (Hanno et al., 2011; Rosamilia, 2005; Rosenberg, Newman, et al., 2007; 
Rothrock et al., 2003).  A case report of 64 women with diagnosed IC/PBS, meeting the 
NIDDK definition of IC/PBS, sought care at a participating clinic.  They completed 
questionnaires and a standardized semi-structured depression interview at scheduled 
clinic appointments (Rothrock et al., 2003).  Participants completed the Beck Depression 
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Inventory, the Hamilton Rating Scale for Depression, and the Medical Outcome Study.  
Regression models were constructed to test the relationships among coping strategies, 
quality of life and depression.  The Beck Depression Inventory (BDI), a 21-item 
instrument that assessed the severity of depressive symptoms on a Likert scale, had 
reliability and validity demonstrated in populations with chronic illness (Rothrock et al., 
2003).  The BDI was studied over a 25 year period with psychiatric and non-psychiatric 
samples.  A meta-analysis of the BDI’s internal consistency estimated an alpha 
coefficient of 0.86 for psychiatric patients and 0.81 for non-psychiatric patients (Beck, 
Steer, & Carbin, 1988). Correlations between the BDI samples with clinical ratings were 
high, 0.72 for psychiatric patients, and 0.60 for non-psychiatric patients.  Correlations 
between the BDI and the Hamilton Psychiatric Rating Scale for Depression were also 
high, 0.73 for psychiatric patients and 0.74 for non-psychiatric patients.  These results 
indicated that the BDI reliably differentiates depression from anxiety and is reliable for 
use across populations (Beck et al., 1988).  The Hamilton Rating Scale for Depression 
(HRSD) is a 21 item structured interview that assessed depressive symptoms over the 
last week.  Depressive symptoms are rated on a 0 to 2 or 0 to 4 scale for severity the 
higher score indicated greater depressive symptoms (Rothrock et al., 2003).  
Correlations between the BDI and HRSD were statistically significant (p < 0.001, r =0.45) 
(Rothrock et al., 2003).  The Medical Outcomes Study 36-Item Short Form (MOS) 
assessed 8 areas of functioning: physical function, role-physical, role-emotional, bodily 
pain, general health, vitality, social functioning, and mental health.  A higher score 
indicated a better quality of life (Rothrock et al., 2003).  The MOS was validated by 
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creating four groups of patients based on clinical criteria differing in severity of medical 
and psychiatric conditions.  Comparisons among these four clinical groups tested the 
validity of the scales in detecting decrements in health status associated with chronic 
medical and/or psychiatric conditions (McHorney, Ware, & Raczek, 1993).  Scores 
between the four patient groups were statistically significantly different (p < 0.01) in all 
8 scales.  Patients with serious medical conditions scored significantly lower (p < 0.01) 
on all scales compared to patients with minor medical conditions (McHorney et al., 
1993).  Rothrock et al. (2003) used age and symptom severity as covariates in these 
models.  Researchers found that age and symptom severity were not associated with 
depressive symptoms or mental health.  However, greater severity of symptoms were 
associated with catastrophizing (HPRSD) (p < 0.05) and venting (p < 0.01) (Beck 
Depression Inventory) (Rothrock et al., 2003).  Seeking instrumental support was 
associated with a decrease in depressive symptoms (p < 0.01).  Younger age (p < 0.05) 
and increased symptoms severity (p < 0.001) were significantly associated with 
increased pain (Rothrock et al., 2003). Maladaptive coping strategies were associated 
with higher levels of depressive symptoms and decreased quality of life in patients with 
IC/PBS (Rothrock et al., 2003).  Authors concluded that psychosocial interventions aimed 
at increasing adaptive coping improved symptoms and quality of life for women with 
IC/PBS (Rothrock et al., 2003).  
 Shorter (2006) in a case study and non-systematic review of literature found that 
anecdotal data gathered from patients and experts demonstrated that eliminating 
certain foods from the diet may decrease pain associated with IC/PBS in most patients.    
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Foods commonly found to exacerbate symptoms included alcoholic beverages, coffee, 
tea, carbonated beverages, tomatoes and certain spices (Shorter, 2006).  Foods that 
exacerbated symptoms for one woman did not exacerbate symptoms for another 
woman with IC/PBS.  Additionally, caution is warranted not eliminate too many foods as 
that may result in a deficiency of essential nutrients (Shorter, 2006).  Tettamani et al. 
(2001) conducted a case control twin study examining the effects of smoking, tea and 
coffee consumption on IC/PBS symptoms.  The authors found that tea consumption and 
smoking were positively associated with symptoms of IC/PBS (p < .05); but coffee 
consumption was not associated with symptoms of IC/PBS.  The association of smoking 
to IC/PBS symptoms may be confounded by genetic factors (Tettamanti et al., 2011). 
Disease and exposure were measured at the same time in this study; therefore, 
conclusions about whether the exposure preceded or resulted from the disease were 
not made. 
 Summary.  
 Strong scientific evidence for the support of using behavior modification for the 
treatment of IC/PBS is lacking.  A few studies showed that there were some benefits to 
stress reduction, behavior modifications, improved coping mechanisms, and diet 
modifications (Chaiken et al., 1993; Rothrock et al., 2003; Tettamanti et al., 2011).  Most 
experts agreed that there was not enough evidence to support the use of behavior 
modifications alone to mange IC/PBS (Dell & Butrick, 2006; Hanno et al., 2011; 
Theoharides, 2007; Unwin, 2011).   
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Multimodal therapy 
 The majority of experts agreed that the best approach to management of IC/PBS 
was through a combination on medications and behavioral therapy.  Scientific studies 
on the treatment of IC/PBS yielded mixed results as to the effectiveness of 
pharmacological treatment versus behavioral management of IC/PBS symptoms.  
Rather, urologists and other experts in management of IC/PBS recommended a 
multimodal approach to therapy tailored to the individual.  
 Most of the evidence on multi-modal management was derived from expert 
opinions.  Experts indicated that management of symptoms focused on attaining an 
acceptable quality of life for women with IC/PBS by treatment of the dysfunctional 
bladder epithelium, associated allergies and neural upregulation (Dell & Butrick, 2006; 
Quillin & Erickson, 2012).  They recommended that oral medications as second line 
therapy or adjunct to enhance behavioral modifications (Dell & Butrick, 2006; Forrest & 
Moldwin, 2008; Quillin & Erickson, 2012). Recommended oral medications included PPS, 
antihistamines such as hydroxysine, and cimetidine, TCAs like amitriptyline, analgesics, 
and skeletal muscle relaxants (Dell & Butrick, 2006; Forrest & Dell, 2007; Forrest & 
Mishell, 2009; Forrest & Moldwin, 2008; Rosamilia, 2005; Rosenberg, Newman, et al., 
2007).  Experts recommended management of IC/PBS should begin with the most 
conservative treatments, including diet modification by eliminating high potassium and 
acidic foods, stress reduction, exercise, bladder training, biofeedback, and pelvic floor 
muscle physical therapy if appropriate (Dell, 2007; Dell & Butrick, 2006; Forrest & Dell, 
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2007; Forrest & Mishell, 2009; Forrest & Moldwin, 2008; Rosamilia, 2005; Rosenberg, 
Newman, et al., 2007).     
 Summary.  
 Current research lacked studies on the effectiveness of a multimodal approach 
to treatment of IC/PBS.  Experts agreed that due to inconsistent results in control trials 
and studies of pharmacological and behavior management of IC/PBS symptoms, the 
best approach to management of IC/PBS is a combination of treatments tailored for 
each patient (Dell, 2007; Dell & Butrick, 2006; Forrest & Dell, 2007; Forrest & Moldwin, 
2008; Theoharides, 2007).  Patient education was a key part of management of IC/PBS.  
Patients should understand a)that the etiology of IC/PBS is not fully understood and b) 
that IC/PBS is a chronic condition for which there is currently no cure.  The goal of 
treatment of IC/PBS is not complete elimination of symptoms, but to achieve a quality 
of life that is acceptable for the patient (Dell & Butrick, 2006; Forrest & Moldwin, 2008; 
Quillin & Erickson, 2012).   
Guideline for Management of IC/PBS 
 Hanno et al. (2011) published the only guideline for IC/PBS.  The American 
Urological Association Guideline for the Diagnosis and Treatment of Interstitial 
Cystitis/Bladder Pain Syndrome (AUA Guideline) is a guideline that provides direction to 
clinicians and patients regarding the symptom recognition of IC/PBS, conducting 
diagnostic procedures, and treatment management.  
 A committee of urologists, nurses and other clinicians with specific expertise on 
IC/PBS developed the AUA guideline.  The committee conducted a systematic review of 
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published articles relevant to the diagnosis and treatment of IC/PBS.  Studies included 
those published in English between 1983 and 2009 (Hanno et al., 2011).  Meta-analysis 
of randomized controlled trials and systematic reviews were used to analyze the 
evidence.  Bodies of evidence received grades of A, B or C to indicate the strength of the 
evidence available for particular recommendations.  Grade A were well-conducted RCTs 
or very strong observational studies; grade B consisted of RCTs with some weakness of 
procedure or generalizability or strong observational studies; observational studies that 
are inconsistent, have small sample sizes or have other problems that confound 
interpretation of data were graded level C (Hanno et al., 2011).  Due to a lack of high 
quality evidence on the diagnosis and overall management of IC/PBS, the diagnosis and 
management portions of the algorithm provided clinical principles or expert opinion 
(Hanno et al., 2011).  The AUA defined a clinical principle as, “a statement about a 
component of clinical care that is widely agreed upon by urologists or other clinicians for 
which there may or may not be evidence in the medical literature” (Hanno et al., 2011, 
p. 2163).  The definition of an expert opinion was, “as a statement that is achieved by 
consensus of the committee based on members clinical training, experience, knowledge 
and judgment for which there is no evidence” (Hanno et al., 2011, p. 2163). 
 The AUA guideline provided an algorithm for diagnosis and treatment, included 
in Appendix C (Hanno et al., 2011). First line treatments recommended by the AUA 
guideline as clinical principles included: a) general relaxation and stress management, b) 
patient education, c) self-care and behavior modification.  Self-care and behavior 
modification included: a) avoiding behaviors that worsen symptoms, b) avoidance of 
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foods that are known bladder irritants such as citrus, c) pelvic floor muscle relaxation, 
and d) bladder training (Hanno et al., 2011).  The use of the oral medications PPS, 
amitriptyline, cimetidine and hydroxyzine were second line treatments due to possible 
minor side effects and unpredictable efficacy for individuals. This recommendation was 
based on evidence graded levels B and C by the committee (Hanno et al., 2011).  The 
AUA Guideline stated that the use of long-term oral antibiotics is an ineffective 
treatment that should not be used for IC/PBS.  The level of evidence for this statement 
is grade B and for this reason, it is considered a standard by the AUA.  The AUA defined 
a standard as a directive statement that an action should or should not be undertaken 
based on Grade A or B evidence (Hanno et al., 2011).  The AUA guideline also listed as a 
recommendation that systemic oral long-term glucocorticoids should not be used to 
manage IC/PBS (Hanno et al., 2011).  The AUA defines a recommendation as, “a 
directive statement that an action should or should not be undertaken based on Grade 
C evidence” (Hanno et al., 2011, p. 2163).  According to the AUA Guideline, the goal of 
treatment of IC is to minimize symptoms and adverse events while maximizing the 
quality of life for patients.  No single treatment has been found that is effective for the 
majority of women with IC/PBS (Hanno et al., 2011). 
To appraise the AUA Guideline for quality of evidence, The Appraisal of 
Guidelines Research and Evaluation (AGREE) instrument was used.  The AGREE 
instrument was designed to appraise the quality of patient care guidelines to determine 
that the recommendations made are internally and externally valid, as well as feasible 
for practice (AGREECollaboration, 2001).  The AGREE instrument used 23 items in the six 
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categories to determine the quality of the recommendations: scope and purpose, 
stakeholder involvement, rigor of development, clarity and presentation, applicability, 
and editorial independence (AGREE Collaboration, 2001).  Each of the items was rated 
on a 4 point scale ranging from 4 strongly agree to 1 strongly disagree.  The category 
score was then determined by standardizing the total as a percentage of the maximum 
possible score for the category (AGREECollaboration, 2001).  Each category score was 
independent and were not aggregated into a single quality score, a threshold for the 
category scores to determine if the guideline is “good” or “bad” was not set 
(AGREECollaboration, 2001).  The scores in each category for the AUA guideline were as 
follows: Scope & purpose 78%, Stakeholder involvement 67%, Rigor 71%, Clarity 92%, 
Applicability 11%, and Editorial independence 67% (AGREECollaboration, 2001; Hanno 
et al., 2011).  The lowest score for the AUA guideline was in the category of applicability.  
According to the AGREE Collaboration (2001), a guideline should discuss potential 
organizational barriers in applying the recommendations, the potential cost of applying 
recommendations and key review criteria for monitoring and audit purposes to measure 
adherence to the guideline.   The AUA guideline did not address monitoring adherence 
or provide criteria for audit purposes (Hanno et al., 2011).  The AUA guideline did 
present statistics on the current cost of IC/PBS and the burden on the patient and 
medical community.  The authors did not address how implementation of their 
recommendations could impact the cost of treatment (Hanno et al., 2011).  The 
intended users of the AUA Guideline are Advanced Practice Nurses, Physician Assistants 
and Physicians practicing in the areas of family practice, internal medicine, obstetrics 
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and gynecology, and urology (Hanno et al., 2011).  The AUA guideline did not make any 
recommendations regarding: a) which treatments should be offered in primary care or 
family practice, b) which would require a referral to a specialist, or c) at what point in 
management of IC/PBS referral is appropriate (Hanno et al., 2011).   Other weaknesses 
of the AUA guideline for IC/PBS were inherent to the lack of available scientific research 
to validate recommendations for the treatment of IC/PBS.  
Summary 
 The purposes of this project are to: 1) conduct a substantive literature review on 
treatment guidelines for IC/PBS, 2) analyze the literature for comparing oral 
pharmacological interventions and behavioral interventions for IC/PBS, and 3) 
determine the best practice recommendation for the management of ICS/PBS in adult 
women, ages 18 and older.  Currently many providers are unfamiliar with IC/PBS and the 
appropriate best practice for managing IC/PBS in women.  Women are commonly 
treated with antibiotics despite negative urine cultures and a lack of response in the 
past to antibiotic therapies (Clemens et al., 2010).  A review of current literature and 
development of best practice recommendation for management of IC/PBS in women 
aids health care providers in recognizing IC/PBS early and initiating appropriate 
treatments, thus decreasing unnecessary and inappropriate treatments and improving 
the quality of life of women with IC/PBS (Clemens et al., 2010; Patel et al., 2008).     
 The scientific studies addressing the management of IC/PBS that are available to 
date focused on the treatment of IC/PBS with pharmacological measures.  The strongest 
evidence in the form of RCTs, meta analysis, cohort studies and case studies focused on 
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the treatment of IC/PBS with pharmacological medications, primarily PPS (Anderson & 
Perry, 2006; Dimitrakov et al., 2007; Hill et al., 2008; Nickel et al., 2005; Nickel et al., 
2008; Sairanen et al., 2005; Sand et al., 2008).  A few case studies reported the potential 
benefit of behavior modification, diet and stress reduction for the management of 
IC/PBS, however strong scientific evidence to support these treatments was lacking 
(Chaiken et al., 1993; Rothrock et al., 2003; Tettamanti et al., 2011).  Many experts 
recommended managing IC/PBS with a multimodal treatment approach (Dell, 2007; Dell 
& Butrick, 2006; Forrest & Dell, 2007; Forrest & Moldwin, 2008; Hanno et al., 2011; 
Theoharides, 2007).  There were many anecdotal cases reports and expert opinions that 
supported this multimodal method of treatment.  However, strong scientific evidence to 
show that a multimodal approach achieved the best patient outcomes was lacking.      
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CHAPTER 3 
GUIDELINE 
 Interstitial Cystitis/Painful Bladder Syndrome is a chronic condition that affects 
approximately 20 to 25 percent of non-pregnant adult women in the United States 
(Burkman, 2004; Parsons, 2002).  Many providers were unfamiliar with the diagnosis 
and management of IC/PBS and patients suffering from the disease were undiagnosed 
or misdiagnosed (Forrest & Moldwin, 2008; Heck, 2007).  It was not uncommon for 
women with IC/PBS to suffer with symptoms for five years or more before they recieved 
the correct diagnosis and appropriate management (Heck, 2007).  Early diagnosis and 
management was shown to lead to better patient outcomes, better response to 
available therapy and increased quality of life (Forrest & Moldwin, 2008; Parsons, 2006).  
Current research showed that primary care providers are unfamiliar with the diagnosis 
of IC/PBS and proper management (Clemens et al., 2010).  In a survey of primary care 
physicians, Clemens et al. (2010) found that many of primary care physicians had 
erroneous beliefs about IC/PBS, including the belief IC/PBS was caused by a psychiatric 
illness or an STD.  Only 67% of the physicians surveyed correctly identified that the 
hallmark symptom of IC/PBS as bladder pain or pressure (Clemens et al., 2010).  
Physicians were also unfamiliar with appropriate treatment and diagnostic testing for 
IC/PBS.  Physicians often conducted tests for Chlamydia and gonorrhea, serum 
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createnine, cervical cultures, and pelvic ultrasounds and treated patients with NSAIDS, 
anticholinergics and antibiotics despite negative urine cultures and no response in the 
past to antibiotic therapies (Clemens et al., 2010). Improving outcomes for women with 
IC/PBS depends on improving healthcare providers’ familiarity with the disease and its 
management.  An evidenced based guideline outlining best practice for the 
management of IC/PBS would improve outcomes for women with IC/PBS.    
Literature Search 
 The search of current literature included a search of guideline databases to 
determine what guidelines on the management of IC/PBS existed.  A search of the term 
“interstitial cystitis” in the National Guideline Clearinghouse (NGC) yielded eleven 
results.  However, only one pertained to IC/PBS, the remaining results included chronic 
pelvic pain, haematuria, incontinence in women, lower UTIs, and cancer.  The guideline 
published by Hanno et al. (2011) was currently the most comprehensive guideline 
available for the management of IC/PBS and was discussed in greater detail in chapter 2.  
The algorithm from this guideline is included in Appendix D.  The algorithm written by 
Hanno et al. (2011) included basic management principles and several levels of 
treatment, implemented in a step-wise fashion or simultaneously based on the 
clinician’s assessment of the patient’s condition.  
 Effective management of IC/PBS depends on accurate diagnosis of the disease.  
Current literature suggested that IC/PBS is diagnosed and managed in the primary care 
setting (Patel et al., 2008). The purpose of the guideline published by Hanno et al. (2011) 
was to provide a clinical framework for the diagnosis and treatment of IC/PBS.  The 
  62 
authors acknowledged that due to a lack of high quality evidence supporting the 
recommendations in this guideline, further RCTs related to diagnosis of IC/PBS were 
needed to improve current practices. 
Recommendation Evidence 
 Management of IC/PBS can be difficult and treatment and should be tailored to 
each individual.  IC/PBS is a chronic disease and a cure or complete relief from 
symptoms is not a realistic outcome for patients at this time.  Appropriate management 
of IC/PBS focuses on reduction of symptoms and improvement of quality of life to a 
level that is acceptable to the patient (Forrest & Mishell, 2009; Sairanen et al., 2009).   
 Non-Pharmacologic Management.  
 The AUA guideline by Hanno et al. (2011) stated that the clinical principle 
treatment of IC/PBS should begin with the most conservative therapy providing 
adequate control of symptoms to support an acceptable quality of life.  A clinical 
principle is a statement that is widely agreed upon by urologists or other clinicians for 
which there may or may not be supporting evidence in the medical literature (Hanno et 
al., 2011).   According to the AUA guideline, a clinical principle for first line treatment 
focuses on pain management, stress reduction, coping techniques, self-care practices, 
and behavioral modifications that improve symptoms (Hanno et al., 2011).  The RCT by 
Chaiken et al. (1993) demonstrated the effective use of behavior modification for 
management of symptoms of urgency, frequency and pain related to IC/PBS.  Chaiken et 
al (1993) found that behavior modification does significantly improve functional bladder 
capacity in women (p < 0.01).  The findings of Chaiken et al. (1993) were not 
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corroborated by newer research because more recent studies of behavior modification 
for the relief of symptoms of urgency, frequency and pain had not been conducted.  
Rothrock et al. (2003) conducted a case report of 64 women with IC/PBS supporting the 
statement by Hanno et al. (2011) that coping techniques improve outcomes for women 
with IC/PBS.  Rothrock et al. (2003) found that maladaptive coping strategies were 
associated with higher levels of depressive symptoms and decreased quality of life in 
patients with IC/PBS.  Self-care practices to improve symptoms of IC/PBS suggested by 
Hanno et al. (2011) included diet modification and avoidance of foods that are common 
bladder irritants such as coffee or citrus products.  In a case study and non-systematic 
literature review Shorter (2006) found that diets must be individualized for each patient, 
as foods that exacerbate symptoms in one woman may not increase symptom flares in 
another.  Foods that were commonly found to increase symptoms were alcoholic 
beverages, coffee, tea, carbonated beverages, tomatoes, and some spices (Shorter, 
2006).  However, a case control study by Tettamani et al. (2001) did not support the 
claim that coffee consumption exacerbates symptoms of IC/PBS.  Tettamani et al. (2001) 
found that coffee consumption was not associated with symptoms of IC/PBS; but tea 
consumption and smoking were positively associated with symptoms of IC/PBS.   
 Research supported the recommendation by Hanno et al. (2011) that behavior 
modifications and coping strategies reduce symptoms in women with IC/PBS (Chaiken, 
Blaivas, & Blaivas, 1993; Rothrock, Lutgendorf, & Kreder, 2003).  However, current 
literature on the effect of diet on symptoms of IC/PBS was inconclusive with outcomes 
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showing varying results that are not consistent among all women with IC/PBS (Shorter, 
2006; Tettamanti et al., 2011).   
  
 Pharmacological Management.  
 Second line therapy recommended as an option by Hanno et al. (2011), was the 
use of oral medications; amitriptyline, cimetidine, hydrosyzine or pentosan polysulfate 
(PPS) for the relief of symptoms associated with IC/PBS.  However, administration of 
these medications was shown to have variable efficacy for individuals.  Their 
administration was associated with minimal adverse effects.  An AUA guideline option is 
a non-directive statement that leaves the decision to take an action up to the individual 
clinician and patient because the balance between benefits and risks or burden appears 
to be relatively equal or unclear (Hanno et al., 2011).  
 The literature found that PPS was effective for the management of IC/PBS and 
that the side effects of this medication were minimal and that in most patients PPS is 
well tolerated (Anderson & Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005; 
Nickel et al., 2008; Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008).  Nickel 
et al. (2005) found that longer duration of PPS and earlier initiation of PPS therapy lead 
to better patient outcomes (Nickel et al., 2005; Nickel et al., 2009).  Based on these 
findings initiation of PPS as therapy for IC/PBS should be a first line treatment rather 
than a second line therapy as recommended by Hanno et al. (2011).  The use of PPS for 
the management of IC/PBS was the most extensively studied oral treatment for IC/PBS.  
PPS is also the only oral medication approved by the FDA for treatment of IC/PBS 
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(Anderson & Perry, 2006).  Several RCTs have examined the use of PPS in management 
of IC/PBS.  Nickel et al. (2005) conducted a RCT on the use of PPS for reduction of 
symptoms of IC/PBS in women.  These researchers found that at the end of the 32 week 
study, 59 to 67 percent of participants had significant improvement in IC/PBS 
symptoms, depending on the dose.  A secondary analysis of this study found that 
initiation of PPS within 6 months of diagnosis with IC/PBS improved ICSI scores by an 
average of 3.97 points compared to an improvement of 2.15 points for women who 
were started on PPS more than 6 months after diagnosis (p < 0.0472) (Nickel, Kaufman, 
Zhang, Wan, & Sand, 2008).  These findings supported the use of PPS for effective 
management of IC/PBS symptoms in women and demonstrated that earlier initiation of 
the medication led to better outcomes.   In a separate secondary analysis of the RCT by 
Nickel et al. (2005), Sand et al. (2008) found that 42% of women who were treated with 
PPS found relief from IC/PBS symptoms.  Women treated with PPS were more likely to 
be pleased with PPS (p<0.0001), more likely to benefit from PPS for IC symptoms (p < 
0.0001), and more likely to recommend PPS for IC symptoms (p < 0.046). These women 
also felt that PPS provided better relief than previous treatments (p< 0.0038) (Sand et 
al., 2008).  A systematic review of RCTs published between 1987 and 2006 examined the 
treatment of IC/PBS with PPS.  In this review Dimitrakov et al. (2007) found, in a pooled 
analysis of six RCTs and one meta-analysis, that treatment with PPS provided symptom 
improvement for patients with IC/PBS with a relative risk for symptom improvement of 
1.78 (Dimitrakov et al., 2007).   
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 The literature showed that use of the medications amitriptyline, cemetidine, and 
hydroxyzine alone for management of IC/PBS was not effective (Hill et al., 2008; Unwin, 
2011).  However, Hanno et al. (2011) recommend the use of Amitriptyline, cimetidine, 
and hydroxysine for the management of IC/PBS.  Dimitrakove et al (2007), in a 
systematic review of literature, concluded that there was insufficient evidence to 
recommend the use of oral pharmacological therapies for the management on IC/PBS 
other than PPS.  A cross-sectional study of 750 patients with IC/PBS found that 
symptoms of IC/PBS were significantly improved with amitriptyline, phenzopyridine, 
Prelief and codeine (Hill, Isom-Batz, Panagopoulos, Zakariasen, & Kavaler, 2008).  In a 
literature review Unwin (2011) found that use of amitriptyline for treatment of pain, 
urgency and frequency associated with IC/PBS was safe and effective.  Best results in the 
mnagment of IC/PBS was using amitriptyline in conjunction with PPS and non-
pharmacological management (Unwin, 2011).   
 Hanno et al. (2011) recommended the use of cemetidine or hydrxyzine as second 
line treatment for IC/PBS, however, current literature did not support the use of 
cimetidine, or hydroxyzine for relief of symptoms associated with IC/PBS (Dimitrakov et 
al., 2007; Unwin, 2011).  Amitriptyline may be effective for relief of IC/PBS symptoms, 
however, studies examining the use of amitriptyline were small and the findings varied.  
PPS is the only oral medication for the management of IC/PBS that was supported by 
high quality RCTs and systematic reviews.   
 As a fifth line approach Hanno et al. (2011) offered the option to use 
Cyclosporine A for the management of IC/PBS, if other treatments had not provided 
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adequate symptom control and quality of life or if the clinician and patient agreed that 
symptoms required this approach.  In a RCT comparing the use of PPS and oral 
cyclosporine A for symptom relief in patients with IC/PBS, Sairanen et al. (2005) found 
that cyclosporine A was significantly more effective the PPS (p<0.001).  However, 
adverse events associated with cyclosporine A administration were more common and 
severe than PPS treatment including increased blood pressure and serum creatinine 
(Sairanen et al., 2009; Sairanen et al., 2005).  Cyclosporine A is not approved by the FDA 
for the management of IC/PBS and clinicians are cautioned that if this treatment is used 
for IC/PBS, the patient must be monitored closely (Sairanen et al., 2009).  While 
cyclosporine A may be effective, the side effects are more severe than PPS.  Currently 
this treatment is not approved by the FDA, therefore providers must use caution if using 
this medication for the management of IC/PBS.         
Best Practice Recommendations 
 A comprehensive review of literature published between 2002 and 2013 found 
that the AUA Guideline by Hanno et al. (2011) is the most comprehensive guideline 
currently available for the management of IC/PBS.  Examination of this guideline and 
other literature that is currently available addressing the management of IC/PBS in adult 
women who are not pregnant found that the following recommendations represent the 
best practice for the use of pharmacological interventions and behavioral interventions 
for the improvement of IC/PBS symptoms in these women.  Each recommendation is 
given a grade based on the quality and amount of evidence available to support the 
recommendation.  The Scottish Intercollegiate Guidelines Network (2011) grades of 
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recommendations were used to grade the evidence.  Grades of A through D were given; 
a grade of an A represents the strongest supporting evidence while D is based on expert 
opinions.  A detailed explanation of each letter grade can be found in appendix D (SIGN, 
2011).  
• Behavioral modification and adequate coping strategies should be first line 
therapy (Chaiken et al., 1993; Hanno et al., 2011; Rothrock et al., 2003).  Hanno 
et al. (2011) addressed the use of general relaxation, stress management, pain 
management, self-care and behavior modification as first line treatment; 
however the authors did not specifically recommend the benefit of learning 
adequate coping strategies that was found to be effective by Rothrock et al. 
(2003).  Grade C 
• Diet modification as part of behavioral modification was not effective.  Current 
literature on the effect of diet on symptoms of IC/PBS was inconclusive with 
outcomes showing varying results that are not consistent among all women with 
IC/PBS (Shorter, 2006; Tettamanti et al., 2011).  Dietary restrictions were 
recommended by Hanno et al. (2011) as part of first line therapy, however 
restrictions increased some patients’ stress levels without providing significant 
relief (Shorter, 2006; Tettamanti et al., 2011).  Grade C 
•  PPS should be offered as a first line therapy for women with IC/PBS (Anderson & 
Perry, 2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; 
Sairanen et al., 2009; Sairanen et al., 2005; Sand et al., 2008).  Hanno et al. 
(2011) included PPS with all other oral medications as second line therapy due to 
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the potential for minor side effects.  However, the literature found that PPS was 
effective for the management of IC/PBS and that the side effects of this 
medication were minimal. Most patients tolerated PPS well (Anderson & Perry, 
2006; Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; Sairanen et 
al., 2009; Sairanen et al., 2005; Sand et al., 2008).  Nickel et al. (2005) found that 
longer duration of PPS and earlier initiation of PPS therapy led to better patient 
outcomes (Nickel et al., 2005; Nickel et al., 2009).  Grade A 
• Amitriptyline, Cemetidine and hydroxyzine should not be used alone for the 
management of IC/PBS. In conjunction with PPS, these may be offered as a 
second line therapy (Dimitrakov et al., 2007; Hill et al., 2008; Unwin, 2011).  
Hanno et al. (2011) grouped all oral medications together as second line therapy, 
these medications should be second line therapy not only due to potential 
adverse effects but also due to varied effectiveness found in the literature 
(Dimitrakov et al., 2007).  The literature showed that use of the medications 
amitriptyline, cemetidine, and hydroxyzine alone for management of IC/PBS was 
not effective, however, use of these medications with PPS showed some benefit 
(Hill et al., 2008; Unwin, 2011). Grade D 
• Cyclosporin A is not recommended for the management of IC/PBS (Sairanen et 
al., 2009; Sairanen et al., 2005).  Hanno et al. (2011) recommended Cyclosporine 
A as a fifth line treatment with an evidence grade of C.  However, the adverse 
events associated with Cyclosporine A administration were more common and 
severe than PPS treatment. Adverse events included increased blood pressure 
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and serum creatinine (Sairanen et al., 2009; Sairanen et al., 2005).  Cyclosporine 
A was not approved by the FDA for the management of IC/PBS and clinicians 
were cautioned that if this treatment is used for IC/PBS, the patient must be 
monitored closely (Sairanen et al., 2009). Grade A  
Summary 
 Management of IC/PBS is challenging and patient care should focus on providing 
adequate relief to the patient with the most conservative treatments possible.  The 
literature showed that behavioral modification and adequate coping strategies 
significantly improve symptoms and quality of life for women with IC/PBS (Chaiken et 
al., 1993; Rothrock et al., 2003).  While several oral medications were suggested for the 
management of IC/PBS, the literature did not show that amitptyline, cimetidine, or 
hydroxyzine significantly improved symptoms of IC/PBS in women; nor improved the 
quality of life in these patients (Dimitrakov et al., 2007; Hill et al., 2008; Unwin, 2011).  
PPS is the only oral medication with the FDA indication for treatment of IC/PBS.  RCTs 
and systematic reviews found that PPS significantly improved symptoms of IC/PBS and 
quality of life with minimal side effects and the medication was generally well tolerated 
(Dimitrakov et al., 2007; Nickel et al., 2005; Nickel et al., 2008; Sand et al., 2008).  Oral 
cyclosporine A was effective in the relief of symptoms of IC/PBS, however, the side 
effects of the medication were common and the risk may out weigh the benefit 
(Sairanen et al., 2009; Sairanen et al., 2005).  Best practice management of IC/PBS 
begins by setting realistic goals with the patient for adequate symptom control and 
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quality of life.  Behavior modifications and coping strategies should be initiated first 
then the use of PPS for symptom relief should be considered.        
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CHAPTER 4 
CONCLUSIONS AND RECOMMENDATIONS 
 This chapter will present recommendations for practice, research, leadership, 
and policy development for the management of IC/PBS in women.  This project has 
identified best practice recommendations for management of IC/PBS based on a 
comprehensive systematic review of the available literature.  Implications of these 
recommendations to promote evidence–based practice for the management of IC/PBS 
could benefit healthcare providers and women with IC/PBS.   
Implications for Practice  
 Currently healthcare providers do not recognize IC/PBS when women initially 
present with symptoms.  The diagnosis of IC/PBS is difficult due to the lack of specific 
histopathologic changes, unpredictable flares and remissions of symptoms early in the 
disease progression, and an extreme variability in presenting symptoms among patients 
(Dell, 2007; Hanno, 2002; Hanno et al., 2011). A survey conducted by Clemens et al. 
(2010) found that primary care physicians were unfamiliar with IC/PBS and many had 
erroneous beliefs about the disease.  Only 61% of primary care physicians surveyed 
correctly understood that IC/PBS was not caused by a psychiatric illness and only 67% 
identified bladder pain or pressure as the hallmark symptom of IC/PBS (Clemens et al., 
2010). This survey also found that many physicians are treating patients with IC/PBS 
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with treatments proven to be ineffective; 33% of primary care providers treated their 
patients with antibiotics despite negative urine cultures and a lack of response to this 
treatment (Clemens et al., 2010).  
 It was estimated that the delay in diagnosis from onset of first symptoms is 
about five years (Heck, 2007).   Misdiagnosis and delayed diagnosis leads to unnecessary 
diagnostic testing, surgical procedures and a decreased quality of life (Forrest & 
Moldwin, 2008; Heck, 2007). Earlier recognition and appropriate treatment reduce the 
negative effects of IC/PBS. 
 The American Association of Colleges of Nursing (AACN) defined one of the 
essentials of the advanced practice nurse with a Doctorate in Nursing Practice (DNP) as 
a strong scientific underpinning for practice (AACN, 2006).  A DNP nurse develops a wide 
knowledge base gleaned from the sciences and the ability to translate that knowledge 
quickly and effectively into practice for the benefit of patients (AACN, 2006).  The 
advance practice nurse with a DNP has the unique skill set to translate into practice the 
current research for the best management of women with IC/PBS.  In collaboration with 
other healthcare providers, the DNP nurse needs to implement the management 
techniques proven in literature to benefit women with IC/PBS, such as oral PPS and 
stress management techniques; and discontinue outdated and ineffective treatments 
such as oral antibiotics and other medications shown to be ineffective.  The DNP nurse 
also participates in the continual gathering and evaluating of current research on the 
management of IC/PBS and translates new findings into clinical protocols to improve 
patient outcomes.  Consistent use of the management techniques for IC/PBS supported 
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by high quality evidence and continuing education on evidence based practice 
guidelines for healthcare providers will lead to better patient outcomes.      
Implications for Research  
 Scholarship and research are the hallmarks of a doctoral level education.  DNP 
nurses participate in scholarship through the translation and application of knowledge 
and the integration and synthesizing of information into practice (AACN, 2006).  Need 
exists for the advancement of the body of knowledge regarding the management of 
IC/PBS in women.  Current well-designed studies on the effectiveness of non-
pharmacological management strategies for IC/PBS are not available.  Further study of 
pharmacological interventions is also needed to better determine the most effective 
way to manage IC/PBS in women.  In addition to participation in gathering new scientific 
knowledge on the management of IC/PBS, DNP nurses have the opportunity to translate 
this research into best-practice protocols for diagnosing and managing IC/PBS in primary 
care and specialty practice.   One of the roles of the DNP nurse as a researcher is to 
collaborate with PhD prepared nurses in discovery research to provide new treatment 
options for patients.  In the practice setting, the DNP nurse enhances research by 
collecting new data.  The DNP nurse partners with other doctoral level practitioners to 
synthesize and interpret this data and make new treatment recommendations.   The 
DNP prepared nurse adds his/her experience from the clinical setting to tailor 
recommendations for the practice setting for implementation and improved patient 
outcomes.   
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Implications for Leadership 
 The Essentials of Doctoral Education for Advanced Nursing Practice published by 
the AACN states that, “doctoral education in nursing is designed to prepare nurses for 
the highest level of leadership in practice and scientific inquiry.” (2006, p.7).  DNP 
graduates are prepared to develop and evaluate care delivery approaches that meet 
current and future needs of patient populations based on scientific findings and 
enhance the quality of health care for populations with whom they work (AACN, 2006).  
The healthcare provider caring for adult women should be familiar with the best 
practice for recognizing and managing IC/PBS.  The DNP nurse demonstrates leadership 
in the field by providing education on best practice management of IC/PBS to other 
healthcare providers to improve quality of care and outcomes for women with IC/PBS.   
 As evidenced by the study by Clemens et al. (2010), and personal experience, 
there is a lack of knowledge and understanding of IC/PBS.  Primary care providers are 
not aware of which patients to screen for IC/PBS or how to treat patients that providers 
suspect have IC/PBS.   
Strategies for this project focused on improving policy in two primary care rural 
settings with a focus on educating providers about IC/PBS diagnosis.  Particular 
attention was given to patients who had been frequently treated for UTIs and either had 
not had a urine culture done or were treated with an antibiotic despite a negative 
culture.   In these rural health care settings, primary care providers had to begin 
treatment for IC/PBS and help the patient manage symptoms.  Providers were educated 
on first line treatments of stress reduction and initiation of PPS to improve patients’ 
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symptoms.  Providers were receptive to education and implementation of 
recommendations into practice.  After receiving continuing education, providers 
conducted urine cultures on every woman frequently presenting with symptoms of UTI 
ruling out the presence of bacteriuria and promoting a possible diagnosis of IC/PBS.  
Implications for Policy development 
 According to the ANCC Essentials for Doctorate Education, DNP graduates must 
be skilled in working within organizational and policy arenas in addition to the actual 
provision of patient care (AACN, 2006).  DNP nurses are proficient in quality 
improvement strategies and in creating and sustaining changes in the organization and 
policy (AACN, 2006).  Leadership from DNP nurses in policy development is essential to 
the nursing profession and the patients they serve (AACN, 2006).   The purpose of 
institutional and practice policies are to ensure best practice, safe practice, optimal 
patient outcomes and cost-effective treatment of patients.  DNP nurses contribute to 
policy development by serving on development councils and contributing to decisions 
made through direct involvement or education of others involved in policy development 
(AACN, 2006).  Policy development in the author’s primary care practice, related to the 
management of IC/PBS, is currently in progress.  This policy will provide guidance on 
treatment of IC/PBS, improving patient outcomes.   
Summary 
 IC/PBS is a chronic condition affecting millions of women in the United States 
that is often unrecognized and undiagnosed (Burkman, 2004; Forrest & Moldwin, 2008).  
DNP advanced practice nurses are in the unique position to manage IC/PBS in women, 
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educate patients and other healthcare providers about the disease, contribute to new 
research, and contribute to the development and implementation of best practice 
guidelines and policies to improve patient outcomes.   
  DNP advanced practice providers use the most current literature to improve 
their practice and patient outcomes.  Literature on the management of IC/PBS 
supported the use of oral PPS for management of IC/PBS (Dimitrakov et al., 2007; Nickel 
et al., 2005; Nickel et al., 2008; Sand et al., 2008).  The literature did not support the use 
of amitrypline, cemetidine, or hydroxyzine for management of IC/PBS (Dimitrakov et al., 
2007; Hill et al., 2008; Unwin, 2011).  Behavior modifications and coping strategies 
provided some symptom improvement (Chaiken et al., 1993; Rothrock et al., 2003).  
Best practice management of IC/PBS should focus on setting realistic goals with a 
patient for an acceptable quality of life, incorporation of behavior medications, 
appropriate coping strategies and oral PPS.  Further research on the management of 
IC/PBS is needed, particularly of non-pharmacological therapy and oral medications as 
alternatives to PPS.  New research and the development of evidence based protocols for 
the management of IC/PBS provides many opportunities for DNP advance practice 
nurses to participate in new research and translation of research into practice.    
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APPENDIX A 
Table A.1: Evidence Tables 
Brief 
Reference 
Type of study/ 
Grade 
Methods Threats to validity/ 
reliability 
Findings Conclusions 
(Anderson & 
Perry, 2006) 
Review of literature/ 
3 
Authors searched 
medical literature 
published in any 
language since 1980 on 
pentosan polysulfate.  
Search engines used 
were MEDLINE, 
EMBASE and AdisBase.  
Results were 
supplemented with 
references from the 
bibliography of 
published articles.  The 
Search terms used were 
‘pentosan polysulfate’ 
or ‘pentosan 
polysulfate’ and 
‘interstitial cystitis’.  
Studies were selected 
for inclusion based on 
methods of selection 
The strength of the 
evidence found was not 
discussed and 
recommendations were 
not graded.  The authors 
state that When 
available large, well-
controlled trials were 
preferred, however, they 
do not discuss how many 
of these studies were 
large well-controlled 
trials.   
PPS is a semi-
synthetic, sulfated 
polysaccharide 
chemically similar to 
heparin.  The exact 
pharmacokinetics are 
not well understood, 
it is thought that it 
repairs the GAG layer 
on the bladder 
epithelium reducing 
permeability to toxins 
from the urine.  It 
may also reduce 
histamine secretion 
thereby reducing 
inflammation.  
Bioavailability of PPS 
is very low.  Well-
designed trials found 
that compared to 
PPS has shown 
beneficial effect in a 
large proportion of IC 
patients.  It improves 
the patients’ overall 
condition and provides 
pain relief.  It is 
generally well tolerated 
and side effects are 
usually mild.  Current 
literature supports the 
use of PPS as an 
important option in the 
treatment of IC.  
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Brief 
Reference 
Type of study/ 
Grade 
Methods Threats to validity/ 
reliability 
Findings Conclusions 
used in the trials.  When 
available large well-
controlled trials were 
preferred.   
placebo PPS was 
more effective at 
treating moderate to 
severe IC.  In patients 
with less severe IC 
PPS was not 
significantly different 
from hydroxyzine and 
less effective than 
cyclosporine.  Non-
comparative studies 
of long-term 
treatment show that 
PPS significantly 
reduces pain over 
time.  Use of PPS and 
heparin was shown to 
be more effective 
than either alone, 
however use of PPS 
and hydroxyzine 
together is not 
significantly different 
than use of either 
alone.   
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(Chaiken et al., 
1993) 
Case study/3 42 women previously 
diagnosed and treated 
for IC were selected to 
participate in 
behavioral therapy for 
refractory symptoms of 
urgency, frequency and 
suprapubic pain related 
to IC. These women 
participated in an 8 to 
12 week course of 1 45-
minute behavioral 
therapy session per 
week.  Women were 
asked to keep a voiding 
journal, inter-voiding 
interval; number of 
micturitions per day 
and a global assessment 
scale were used to 
measure effectiveness 
of therapy. An 
experienced therapist 
with training in 
psychology and lower 
urinary tract 
physiology performed 
therapy.  Baseline 
values for total 
daytime void 
volumes, maximum 
Data rely on the 
accuracy of participants 
to a keep a voiding 
journal.   16 participants 
were excluded from the 
results because of a 
failure to keep the 
voiding journal.  
Behavioral therapy 
requires highly 
motivated patients and 
skilled therapist many IC 
patients may not comply 
with the requirements of 
this therapy.  All women 
participating in this study 
had tried other 
treatments for IC such as 
medications, intravesicial 
instillations, and 
mechanical 
interventions, none of 
which provided lasting 
relief, these women may 
be more motivated to 
complete behavioral 
therapy than the average 
IC patient.   
21 participants 
reported that their 
global assessment 
scale symptoms ere 
markedly improved, 
and 16 stated that 
they were improved.  
Those who had 
markedly improved 
symptoms had an 
average increase 
interval between 
voids of 123 minutes 
and an average of 
voiding 6 times per 
day. The functional 
bladder capacity 
increased in 38 of 
42 patients 
(p<0.01), inter-
voiding interval in 
creased in all 
patients by an 
average of 93 
minutes (p<0.01), 
the maximum 
interval increased in 
38 of 42 patients 
(p<0.01) and 41 
patients 
Behavioral therapy 
does improve global 
symptoms assessment 
scores and increases 
intra voiding intervals, 
and decreases number 
of voids per day.  This 
therapy is effective for 
the highly motivated 
patient who has access 
to a skilled therapist.  
However only a small 
percentage of patients 
with IC agree to 
undergo this 
treatment, as it is labor 
intensive.  
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voided volume, mean 
voided volume, 
maximum and mean 
inter-voiding intervals 
and total number of 
micturitions were 
recorded. Post 
treatment values in 
the same categories 
were determined and 
patients were asked 
to rate their global 
results of therapy as 
markedly improved, 
improved, 
unimproved or worse.  
This data was then 
analyzed with the 
student’s t test. 
experienced a 
decrease in the 
number of 
micturitions a day 
by an average of 9 
(p<0.01).  
(Dell, 2007) Expert opinion/ 4 Dell presents a review 
of literature related to 
the differentiation 
between UTIs and 
IC/PBS, and the 
diagnosis and 
management of IC/PBS 
Dell does not rate the 
evidence that he has 
reviewed leaving it hard 
for the reader to draw 
their own conclusions as 
to how reliable the 
recommendations are.   
IC/PBS is a challenge 
to diagnose as 
patients have a range 
of symptoms that 
overlap with other 
disorders, such as 
UTI.  May patient s 
are treated 
empirically with 
antibiotics even 
though their urine 
A urine culture is all 
that is needed to 
differentiate a UTI from 
possible IC/PBS.  IC/PBS 
is more common than 
once thought, patient 
care can be improved 
by completing a urine 
culture on patients 
presenting with irritate 
voiding symptoms.  
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cultures are negative 
and they are later 
diagnosed with 
IC/PBS 
Management should 
focus on a multimodal 
approach combining 
oral and intravesical 
pharmacological 
treatment with diet 
and lifestyle 
modification and other 
non-pharmacological 
potions, including 
stress reduction, 
exercise, bladder 
training, biofeedback 
physical therapy.   
(Dell & Butrick, 
2006) 
Literature review and 
expert opinion/ 4 
The method of 
literature review was 
not discussed in this 
publication.   
 
The method of literature 
review was not 
discussed, the quality of 
articles found and used 
in the article were not 
graded making it difficult 
to judge the quality of 
these recommendations.   
The exact cause of IC 
is unknown making 
finding a targeted 
cure impossible.  
Recent experience 
demonstrates that 
symptoms can be 
managed.  A 
scientifically rational 
approach is a 
multimodal 
treatment strategy 
directed toward 
treatment of the 3 
components 
considered key to the 
pathogenesis of IC.  
The dysfunctional 
Non-pharmacologic 
therapies that can be 
combined with 
medications to 
enhance outcomes 
include diet 
modification to avoid 
foods high in potassium 
and acid.  In patients 
with pelvic pain 
associated with 
concomitant pelvic 
floor muscle 
tenderness and spasm 
restoration of normal 
tone and function 
though physical 
therapy and home 
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bladder epithelium, 
associated allergies, 
and neural 
upregulation.  The 
benefits of 
pharmacologic 
interventions can be 
enhanced with 
dietary changes, 
physical therapy and 
bladder retraining.   
exercise to realign the 
sacrum and ileum by 
internal direct manual 
therapy of the pelvic 
floor muscles is helpful.  
Bladder training and 
biofeedback are also 
helpful.  Pharmacologic 
treatment should start 
with the only FDA 
approved medication 
for IC pentosan poly 
sulfate sodium (PPS).  
PPS appears to 
replenish the defective 
mucous layer and 
restore bladder 
integrity it is currently 
the most effective 
treatment for IC.  Other 
pharmacologic 
treatments that may be 
used in conjunction 
with PPS include 
antihistamines, TCAs, 
analgesics, 
anticholinergics, 
estrogen creams and 
cycle suppression with 
continuous OCPs, and 
skeletal muscle 
relaxants.   
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(Dimitrakov et 
al., 2007) 
Systematic review of 
RCT/ 1++ 
RCT for pharmacologic 
treatment of patients 
with IC diagnosed based 
on the NIDDK definition 
of IC or operational 
criteria were included in 
the review.  Nine 
databases were 
searched including 
Pubmed, CINAHL, Web 
of Science the Cochrane 
Collaboration Reviews 
and others.  Terms 
included Interstitial 
cystitis, and painful 
bladder syndrome.  
Other key words were 
those that described 
the publication as 
randomized, double 
blind, random 
allocation, placebo, 
clinical trial and 
comparative study.  All 
studies were limited to 
those published in 
English and those that 
studied adults.  Only 
trials for PPS had 
sufficient numbers to 
allow a pooled analysis.   
A total of 1470 adult 
The patient sample was 
heterogeneous, possibly 
making generalization to 
the general population 
difficult. There was 
considerable variability 
in the definition of 
symptoms and in 
outcome assessments 
among the RCTs 
reviewed.    
A pooled estimate of 
the effect of PPS 
therapy suggests 
benefit from this 
therapy with a 
relative risk of 1.78 
for patient-reported 
improvement in 
symptoms.  Current 
evidence also 
suggests that 
dimethyl sulfoxide 
and amitriptyline are 
effective therapy for 
IC.  Hydroxyzine, 
intravesical bacilli 
Calmette-Guerin and 
resiniferatozin 
therapies failed to 
show significant 
efficacy.   
PPS therapy has shown 
modest improvement 
in symptoms of IC.  
There is insufficient 
evidence to 
recommend other 
pharmacological 
therapies.   
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patients from 21 RCT 
were used.   
(Forrest & Dell, 
2007) 
Clinical article/ 4 Methods of literature 
review are not 
discussed 
This article is based on a 
review of literature and 
expert opinion.  The 
strength of the literature 
and the qualification of 
the authors are not 
presented.   
PCPs, urologists, and 
OB/GYNs have the 
opportunity to detect 
and provide effective 
management of IC in 
its early stages. 
Treatment should 
include counseling on 
lifestyle modification 
to avoid triggers such 
as high potassium 
foods, and allergens.  
First line therapy is a 
combination of oral 
medications including 
PPS.  Preliminary data 
shows that 
intravesical treatment 
may help relieve 
symptoms in the 
period before PPS 
reaches its full effect.  
Patients should be 
reevaluated between 
1 and 3 months of 
starting treatment.  
Biofeedback and 
neurostimulation 
have also been shown 
to be effective.    
Management of IC is 
multimodal using a 
multi drug oral regimen 
including PPS.  And 
other therapies 
patients may require 
including intravesical 
instillations, 
biofeedback, and 
neurostimulation.   
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(Forrest & 
Mishell, 2009) 
Expert opinion/4 Recent literature was 
reviewed by a panel of 
leaders in urology, 
gynecology, 
urogynecology and 
general women’s health 
to reach a consensus 
and formulate 
algorithms for 
diagnosing and treating 
IC/PBS 
The paper is based on 
the consensus of experts 
and the “recent 
literature reviewed” is 
not described or ranked.  
IC is the cause of a 
large portion of 
chronic pelvic pain 
(CPP), suggesting that 
the diagnosis of IC 
should be a diagnosis 
of inclusion, and 
should be considered 
at the same time as 
other common 
diagnoses rather than 
only when other 
causes have been 
ruled out.  Primary 
goals of treatment 
are relief of pain and 
improvement of 
quality of life. The 
factor that correlated 
most strongly with 
favorable therapeutic 
response was 
duration of symptoms 
prior to treatment; 
early treatment 
provides better 
outcomes.       
Many women with CPP 
are symptomatic for 
longer than necessary 
because of missed or 
late diagnosis.  IC 
should be considered 
as a source of CPP early 
in the diagnostic 
process to prevent 
unnecessary 
gynecologic surgery.  
Clear diagnostic criteria 
for IC must be 
identified; the hope of 
the expert panel is that 
the algorithms 
provided here serve 
that purpose.   
PPS has undergone 
prospective 
randomized trials and 
was shown to have 
significant symptom 
improvement over 
placebo.  90% of 
patients report that 
certain foods 
exacerbated 
symptoms.  Multimodal 
treatment should 
include a behavioral 
component to optimize 
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patient outcomes.   
(Forrest & 
Moldwin, 
2008) 
Review of literature 
and expert opinion/4 
Experts in management 
of IC/PBS discussed 
tools available to 
diagnose and treat IC 
and the advantages and 
disadvantages of each 
approach.  Researchers 
also reviewed literature 
for relevant articles on 
the background, 
diagnosis, and 
treatment of IC with a 
focus on the 
importance of early 
intervention.   
The authors do not 
discuss the qualifications 
of the experts who 
contributed to this 
review.  They also do not 
discuss the quality of the 
literature available and 
reviewed.   
Diagnostic options for 
IC include history and 
physical exam, lab 
evaluations, symptom 
screening tools, 
cystoscopy with 
hydrodistention, 
bladder biopsy, PST, 
ABC, urodynamics 
and urinary markers.  
Treatment options 
include oral and 
intravesical 
medications, dietary 
modifications and 
physical therapy.  
Patient follow –up is 
an important 
opportunity for 
education.   
Most treatment 
options take time to 
take full effect 
encouragement to 
adhere to treatment 
plan is important.  Non-
pharmacological 
treatments such as 
dietary modification, 
stress and anxiety 
reduction, exercise, 
physical therapy, 
counseling, bladder 
training and pelvic floor 
rehabilitation can be 
beneficial and enhance 
pharmacologic 
management.  
Regardless of 
treatment approach 
early identification of IC 
improves patient 
outcomes.   
(Hanno et al., 
2011) 
Guideline 
 
Guideline  
AGREE Score:  
 
Scope & 
purpose=78% 
Stakeholder 
A committee of 
urologist, nurses and 
other clinicians with 
specific expertise on 
IC/PBS developed the 
AUA guideline.  The 
committee conducted a 
systematic review of 
Only the database of 
MEDLINE was searched, 
possibly limiting the 
search and excluding 
some valuable studies.  
Because of a lack of 
evidence expert opinion 
is used to make some 
First through sixth 
line treatments were 
recommended.  A 
treatment algorithm 
was provided to 
summarize these 
findings.  First line 
treatment is 
IC is best managed 
through a logical 
algorithm such as the 
one presented in this 
paper.  Diagnosis and 
treatment options can 
be expected to change 
as there is currently 
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involvement=67% 
Rigor= 71% 
Clarity=92% 
Applicability=11% 
Editorial 
independence=67% 
 
MEDLINE of 
publications in English 
published between 
1/1/1983 and 
7/22/2009.  Meta-
analysis of Randomized 
controlled trials and 
systematic review were 
used to analyze the 
evidence.  Grades of A, 
B or C were given to 
bodies of evidence to 
indicate the strength of 
the evidence available 
for particular 
recommendations.  
Grade A were well-
conducted RCTs or very 
strong observational 
studies; grade B 
consisted of RCTs wit 
some weakness of 
procedure or 
generalizability or 
strong observational 
studies; Observational 
studies that are 
inconsistent, have small 
sample sizes or have 
other problems that 
confound interpretation 
of data were graded 
recommendations rather 
than systematic review 
of literature.  By limiting 
the included studies to 
those conducted in the 
US it is possible that 
valid treatments that 
should be considered 
have been excluded.  
The cost of these 
recommendations is not 
address the authors also 
do not provide 
monitoring criteria for 
audit because this is 
inherently difficult with 
this disease process.  
They also do not provide 
a process for 
revision/update but 
simply state that the 
guideline will be 
updated, as more 
research is available. The 
panel chosen to write 
this guideline is made up 
of experts in Urology and 
IC/PBS; there is a full 
disclosure of any 
conflicts of interest.     
considered to be 
general relaxation 
and stress 
management, pain 
management, 
education and 
behavior 
modification.   Pain 
management should 
be addressed at all 
stages of treatment.   
little evidence on the 
subject and as more 
evidence is provided 
recommendations will 
change.  No single 
treatment is found 
effective for the 
majority of IC patients.  
First line treatment is 
education, self-care 
practices and 
behavioral 
modifications such as 
diet changes, stress 
management and 
pelvic floor muscle 
relaxation and bladder 
training.  PPS and other 
prescription 
medications are 
considered second line 
treatment because 
administration is 
associated with minor 
adverse events and 
efficacy for individuals 
is unpredictable.    
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level C.  Insufficient 
evidence was found on 
the diagnosis o f IC/PBS 
recommendations were 
made based on clinical 
principles and expert 
opinions. The AUA 
defines clinical principle 
as a statement about a 
component of clinical 
care that is widely 
agreed upon by 
urologists or other 
clinicians for which 
there may or may not 
be evidence in the 
medical literature.  
Expert opinion is 
defined as a statement 
that is achieved by 
consensus of the 
committee based on 
members clinical 
training, experience, 
knowledge and 
judgment for which 
there is no evidence. 
The Cochrane Risk of 
Bias tool was used to 
assess individual studies 
that were RCTs.  Studies 
addressing treatments 
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not available in the US 
using herbal 
supplements and 
information collapsed 
across multiple 
interventions were 
excluded.    
(Hill et al., 
2008) 
Cross sectional 
survey/3 
750 patient diagnosed 
with IC completed a 
computerized Internet 
survey that was linked 
on the Interstitial 
Cystitis network, 
national Women’s 
Health Network and 
Our Bodies Ourselves 
websites.  The survey 
questioned patients 
about demographics, 
symptoms, co 
morbidities, treatments 
and perceived 
treatment outcomes. 
Statistical analysis was 
conducted using SPSS 
statistical software, 
descriptive statistics 
were calculated and 
person chi-squared 
tests were used to 
compare the 
percentage of patients 
Survey studies are 
subject to risks involving 
inaccurate self-reporting.   
Hydrodistention, 
intravesicular 
therapy, and urethral 
dilation were the 
most common 
invasive treatments 
used.  Of these 
procedures 27-49.8% 
of patients felt no 
effect, 24.4-45.3% 
were improved, and 
25.9-30.7% felt 
symptoms worsened. 
2.7% (395) of the 750 
individuals surveyed 
had taken PPS 53.4% 
found that the 
medication improved 
IC symptoms, 3.8% 
felt that it made 
symptoms worse, 
29.9% felt that it did 
not have any effect 
and 12.9% of patients 
felt PPS side effects 
The majority of patient 
reported that 
medications improved 
their condition.  
Medical therapy is 
perceived to be better 
than invasive therapy 
for IC.  Medications 
that were perceived to 
improve IC symptoms 
include PPS, calcium 
glycerophosphate 
(Prelief OTC),  
Amitriptylne, 
phenazopyridine, and 
Codine. Vistaril, 
tolterodine, 
oxybutynin, 
oxybutyninXL, and 
diphenhydramine 
appear to have no 
significant effect on IC 
symptoms.   
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who fell into each of the 
three groups based on 
their perceptions of 
each treatment: 
improved, no effect or 
made worse. 
were intolerable 
(P<0.001).  Other 
medications that 
significantly improved 
patients’ perception 
of IC symptoms 
include 
phenazopyridine, 
calcium 
glycerophosphate 
(Prelief), 
amitriptyline, and 
codeine.  Vistaril, 
tolterodine, 
oxybutynin, 
oxybutyninXL, and 
diphenhydramine 
were reported by the 
majority of patients 
to have no effect on 
IC symptoms 
(p<0.001).   
(Nickel et al., 
2005) 
RCT, double-blind/ 
1+ 
Three dosages of 
pentosan polysulfate 
sodium (PPS) were 
evaluated in a 
randomized, double 
blind, double-dummy, 
parallel-group 
multicenter 32-week 
study.  380 adults with 
a diagnosis of IC were 
The completion rate of 
the study was 60%, not 
unexpected by the 
authors given the length 
of the study.  There was 
not a comparable 
placebo group.  Most of 
the patients who 
participated in this study 
had moderate to sever 
No statistically 
significant difference 
in response among 
the three dosages of 
PPS was found.  There 
was significant 
improvement in the 
average ICSI scores 
(p<0.001) over the 
32-week period in all 
Dosages of 300mg, 
600mg, and 900mg of 
PPS all show clinically 
significant results in 
reduction of symptoms 
of IC, however the 
difference between the 
dosage groups is not 
significant.  Duration of 
therapy appears to be 
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randomly assigned to 
dosage groups of 300 
mg, 600 mg or 900 mg 
of PPS.  Patient 
symptoms at base line 
at points during the 
study and at the end of 
the 32 weeks were 
evaluated using the 
O’Leary-Sant IC 
Symptom Index (ICSI) 
and the Patient’s 
Overall Rating Symptom 
Index (PORIS).  Results 
were analyzed using a 
two sample t test and 
chi square analyses with 
a significance level of 
alpha=0.05.   
symptoms of IC and a 
better understanding of 
the treatment effect of 
PPS may be gained by 
studying patients in early 
stages of IC.    
dosage groups.  
Earliest improvement 
in ICSI scores was 
seen in 4 weeks.  
Patients with severe 
baseline symptoms 
responded better to 
600mg dose of PPS 
(p=0.028).  17-23% of 
participants saw 
improvement in ICSI 
scores in 4 weeks by 
the end of the study 
(32 weeks) 59 to 67% 
found improvement 
of symptoms.   
more important that 
the dosage of PPS.  
Over half of study 
participants found 
relief by the end of the 
32-week period even if 
they did not have 
significant symptom 
relief at the four-week 
measurement. Even 
though this study lacks 
a control group and 
participants were IC 
patients with moderate 
to sever symptoms the 
methodology of this 
trial provides strong 
scientific evidence to 
support therapy 
including PPS as 
beneficial for the relief 
of symptoms in women 
with IC.   
(Nickel et al., 
2008) 
Secondary analysis of 
RCT/2- 
Retrospective 
secondary analysis of a 
previously published 
32-week multi center 
randomized, double 
blind. A subset of 128 
women who received 
PPS 300mg/day were 
analyzed in this study.  
The original RCT did not 
have a placebo group. 
The time from diagnosis 
to initiation of PPS was 
used to evaluate time 
until initiation of 
treatment and is not 
representative of time 
since IC symptoms 
The ICSI score for the 
early treatment group 
had an average 
improvement score of 
3.97 points compared 
to an improvement of 
2.15 points in the late 
treatment group 
(p=0.0472).  The ICPI 
Early recognition of IC 
and prompt initiation 
of treatment may lead 
to more improvement 
in IC symptoms and 
response to therapy.  
Individuals treated with 
PPS within 6 months of 
diagnosis showed 
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Participants were 
further sub-categorized 
as receiving early 
treatment with PPS 
(initiation with in 6 
months of diagnosis 
with IC) and late 
treatment (initiation of 
treatment 24 months or 
more after diagnosis of 
IC).  Outcome measure 
included the ICSI and 
the ICPI. Scores from 
the ICSI and ICPI were 
compared using an 
analysis of covariance 
ANCOVA  model that 
included the category 
for time since IC 
diagnosis as a factor 
and baseline score as a 
covariate.  All statistical 
tests were performed at 
a 5% significance level.     
began, especially since 
many patients with IC 
suffer from symptoms 
for moths or years 
before diagnosis. Both 
the early and late 
treatment groups had 
moderate to sever IC 
symptoms at baseline 
making it difficult to 
generalize to patients 
who experience mild IC 
symptoms.  The majority 
of patients had also 
received at least on IC 
medication before 
enrollment in the study, 
which may have created 
an unknown bias.   
showed similar 
results with an 
average improvement 
of 3.94 points from 
baseline in the early 
treatment group and 
1.77 points in the late 
treatment group 
(p=0.0117). This 
exploratory analysis 
suggests that subjects 
with IC benefit from 
earlier initiation of 
PPS therapy.  Those 
who received PPS 
within 6 months of 
diagnosis showed 
significantly greater 
improvement in both 
ICSI and ICPI scores.    
significant 
improvement in 
symptoms scores and 
symptom bother scores 
compared to those who 
did not receive PPS 
until 24 moths or more 
after diagnosis.  Earlier 
initiation of therapy for 
IC may provide more 
benefit to patients 
diagnosed with IC.  
Early diagnosis and 
treatment may be the 
key to better 
management of IC and 
maybe prevention and 
progression of the 
disease.   
(Onwude, 
2009) 
Literature review/ 4 Externally peer 
reviewed clinical article 
published in the British 
Medical journal with 
the goal of highlighting 
areas of practice where 
management lacks 
supporting evidence.   
The method of literature 
review is not discussed.  
The quality of literature 
available is not 
discussed, the author 
does note that the 
quantity of quality 
evidence is lacking.  
IC currently has no 
standardized 
treatment and 
current randomized 
drug studies offer 
conflicting results.   
A systematic review of 
oral treatments for IC is 
needed.  Patients and 
clinicians should 
understand the 
limitations of evidence 
for current treatments 
and set realistic 
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treatment goals.   
(Parsons, 
2002) 
Non-systematic 
review of literature 
and expert opinion/4 
Discussion of IC through 
review of literature and 
author’s experience as 
an expert in treating IC 
for 20 years.   
The rigor to which the 
literature was reviewed 
was not discussed.  The 
author relies on 20 years 
of experience and the 
treatment of more than 
5,000 IC patients to give 
himself credibility as an 
expert.   
IC is a relatively 
common disorder 
that cam be 
recognized in its early 
stages and treated 
with a high measure 
of success.   
Treatment should be 
based on restoring 
epithelial function with 
heparinoids such as 
intravesicular heparin 
or oral PPS; modulating 
neural activity, with 
TCAs; and controlling 
allergies.   Oral PPS had 
been effective in 
treating IC, duration of 
treatment is more 
important than dose.  
Yong patients 18-30 
generally have good 
symptom improvement 
with oral PPS over 2-4 
months.   
(Parsons, 
2006) 
Expert opinion/ 4 The article summarizes 
the latest advances in 
medical treatment of IC 
based on opinions of 
experts in the field and 
their experiences in 
practice.   
This article is based on 
clinicians’’ experience in 
treating women with IC 
rather than rigorously 
designed clinical trials.   
Most individuals are 
affected by a mild to 
moderate form of IC 
that responds to 
treatment.  A 
heparinoid-based 
multi modal medical 
regimen can 
effectively control 
symptoms and 
address disease 
pathology.  
Intravesical solutions 
PPS has been shown to 
successfully treat IC in 
RCT however these 
studies do not explore 
the added benefit of 
longer duration of 
treatment and use with 
ancillary treatments.  
Duration of PPS 
treatment is at least as 
important as dose.  
Heparinoid therapies 
do not treat the 
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are new and 
promising adjunctive 
therapies that can 
offer immediate 
symptom relive in 
flares.   
symptoms of IC they 
correct the dysfunction 
of the epithelial lining 
of the bladder.  
Successful 
management of IC is 
achieved through 
multimodal therapy 
with heparinoid 
therapy.   
(Quillin & 
Erickson, 2012) 
Review literature and 
expert opinion/ 4 
The authors review the 
AUA guideline on the 
diagnosis and 
treatment of interstitial 
cystitis/bladder pain 
syndrome and 
comments on the 
practical 
implementation of the 
guideline and the most 
recent research.   
Strength of other 
literature reviewed is not 
discussed.  Very little 
guidance is added to 
treatment approach 
other than what is 
offered by the AUA 
guideline itself.    
Treatment should 
progress form 
conservative to more 
invasive therapies 
with the goal of 
attaining acceptable 
quality of life.   
 
Assessment of 
symptom level and 
reassessment post 
intervention 
evaluates efficacy.   
 
Concurrent 
treatments may be 
used if in the 
patient’s best 
interest.   
 
Pain management 
should be continually 
Diagnosis of IC/PBS is 
now made based on 
history, physical exam, 
frequency-volume 
chart, UA, and culture 
not on cystoscopy or 
urodynamics.   
 
Treatment focuses on 
education, diet, and 
stress management.  
Oral medications and 
bladder instillations 
should be considered 
second line therapy 
and side effects and 
polypharmacy should 
be avoided.   
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assessed.   
 
Self care practices 
and behavioral 
modification should 
be discussed and 
implemented first.   
 
Amitriptyline, 
cimetidine, 
hydroxyzine, or PPS 
may be administered 
as second-line oral 
medications.   
(Rosamilia, 
2005) 
Clinical article/ 4 The methods of 
literature review were 
not discussed in this 
article.  The author does 
make treatment 
recommendations and 
gives each 
recommendation a 
grade, however she 
does not define her 
grading system or 
discuss her evidence.   
The lack of a methods 
section makes it difficult 
to determine the 
strength of evidence 
reviewed for these 
clinical 
recommendations.  
This article reviews 
the definition, 
diagnosis and etiology 
of IC for the clinician 
and provides graded 
recommendations for 
management 
including physical 
therapy, behavior 
modification, diet 
manipulation, oral 
therapy, and 
intravesical therapy.   
Behavior modification, 
physical therapy and 
dietary manipulation 
are all offered as 
treatments for IC, 
however the author 
does not provide a 
grade for these 
recommendations.  
Treatment with PPS 
and Amitriptyline 
received a grade B 
recommendation, and 
evidence for treatment 
with Hydroxysine, 
Cimetidine, 
immunoregulators, 
antibiotics, 
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cyclosporine and 
analgesics was limited 
leading to a grad D 
recommendation.  
(Rosenberg, 
Newman, et 
al., 2007) 
Clinical article/ 4 Methods of collection 
of literature are not 
discussed.  
Unable to determine the 
strength of the data used 
to complete this article.   
Over time IC/PBS can 
become debilitating, 
and result in 
limitations to 
patient’s personal 
and professional life.  
Patients with IC/PBS 
are 5 times more 
likely to be treated 
for an emotional 
disorder than those 
without IC.  The 
cornerstone of 
treatment is 
behavioral therapy.  
This included 
educating patients 
about symptoms, 
behavioral 
modification to 
decrease urgency and 
frequency, physical 
therapy to release 
trigger points, stress 
reduction, and diet 
modification.  
Multimodal 
pharmacotherapy 
IC has a higher 
prevalence that once 
realized.  IC/PBS has a 
significant impact on 
the quality of life.  Early 
identification and 
initiation of therapy 
leads to better 
outcomes.  Multimodal 
therapy including 
behavioral therapy and 
multiple drugs are the 
standard treatments. 
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consists of PPS, 
hydroxyzine, and 
Amitriptyline.   
(Rothrock et 
al., 2003) 
Case reports/3 64 women with IC were 
recruited from the 
department of urology 
and the participating 
institution.  All were 
diagnosed with IC based 
on the NIDDK 
guidelines.  Participants 
completed 
questionnaires 
assessing depression, 
quality of life, coping, 
and symptom severity 
and a standardized 
semi-structured 
depression interview.  
Descriptive statistical 
analysis was performed 
for demographic 
variables.  For each 
dependent variable 
regression models were 
constructed to test the 
relationships among 
coping strategies, 
quality of life and 
depression.  Age and 
symptom severity were 
covariates in these 
89.1% of the sample was 
white and the majority 
of participants were high 
school graduates or 
higher level of 
education, this sample 
may not be 
representative of the 
general population of 
women with IC.  The use 
of the NIDDK guidelines 
for diagnosis of IC is 
considered to be too 
restrictive for clinical 
practice.  Women in this 
study may differ in 
symptom severity from 
the average women with 
IC because they meet 
these strict criteria for 
diagnosis.   
Age and symptom 
severity were not 
associated with 
depressive symptoms 
or mental health.  
However, greater 
catastrophizing was 
related to more sever 
symptoms on all 
measures of mental 
health (p<0.05).  
Venting was 
associated with more 
depressive symptoms 
(p<0.01) while 
seeking instrumental 
support was 
associated with a 
decrease in 
depressive symptoms 
(p<0.01).  Yonger age 
(p<0.05) and 
increased symptoms 
severity (p<0.001) 
were significantly 
associated with 
increased pain. 
Maladaptive coping 
strategies are 
associated with higher 
levels of depressive 
symptoms and 
decreased quality of 
life in patients with IC.  
Psychosocial 
interventions aimed at 
increasing adaptive 
coping may improve 
outcomes for women 
with IC.   
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models.  All analyses 
controlled for age.    
(Sairanen et 
al., 2005) 
Randomized Control 
trial/1+ 
64 patients meeting the 
NIDDK criteria for 
diagnosis with IC were 
enrolled in a 
randomized prospective 
study.  Participates 
were randomly 
assigned to treatment 
groups with 1.5 mg/kg 
CyA BID or 100mg of 
PPS TID for a 6 month 
period.  Daily 
micturition frequency 
and ICSI and ICPI were 
used to evaluate 
treatment success.  
Baseline factors were 
compared with t test 
and the Mann-Whitney 
rank sum test, and 
differences between 
treatment outcomes 
were calculated with 
the Mann-Whitney rank 
sum test.   
The NIDDK criteria for IC 
is very restrictive and 
this study may not be 
representative of how all 
IC patients would react 
to treatment, 
particularly those with 
early onset, mild 
symptoms.  Sample size 
was relatively small 29 
patients completing the 
study in each treatment 
group.   
Reduction of 
micturition frequency 
in 24 hours by 50% 
was not seen in any 
of the patients in the 
PPS treatment group, 
and in 11 (34%) of 
patients in the CyA 
group (p<0.001).  CyA 
was also significantly 
more effective than 
PPS in all other 
parameters measured 
(p<0.001).   
Researchers state that 
PPS has not been found 
effective for IC patients 
meeting the NIDDK 
criteria for diagnosis, 
however, it is possible 
that PPS works better 
for patients with a 
milder form of IC and in 
earlier stages.  CyA 
treatment is 
recommended for 
patients with severe IC 
meeting the NIDDK 
criteria, particularly 
those who have failed 
other treatments.  
Careful follow up 
including regular 
monitoring of BP and 
serum creatinine is 
mandatory.   
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(Sairanen et 
al., 2009) 
Second analysis of 
Randomized control 
trial/1- 
2 consecutive studies of 
treatment for IC/PBS 
were conducted.  One 
compared 75 patients 
with IC were 
randomized into either 
the DSMO intravesicular 
treatment group or the 
BCG intravesicular 
treatment group.  The 
second study 64 
patients were 
randomized into either 
oral cyclosporine A 
treatment group or PPS 
treatment group.  All 
patients included had to 
meet NIDDK criteria for 
diagnosis with IC.  QOL 
was evaluated with a 
30-item questionnaire.  
Questionnaire results 
were evaluated for each 
treatment group using 
the Wilcoxon rank sum 
test.  A one-way ANOVA 
was used to evaluate 
the similarity of 
baseline characteristics 
of treatment arms.   
Self reported 
questionnaires are 
always subject to bias.  
Also treatment groups 
were relatively small.  
The use of NIDDK criteria 
for diagnosis with IC may 
have limited inclusion of 
patients with IC and limit 
the study’s ability to be 
generalized to the larger 
population of women 
with IC.    
All patients who 
showed a response to 
their specific 
treatment had an 
improved score on 
QOL questionnaires.  
CyA treatment group 
had more 
improvement in 
emotional well-being, 
social functioning, 
activity limitation and 
physical capacity than 
PPS (p<0.001).  More 
patients responded to 
DMSO than BCG 
(p<0.01), but results 
on QOL 
questionnaires were 
equal after either 
treatment.   
The health related 
quality of life 
questionnaire could be 
used to evaluate QOL in 
patients with IC.  It has 
never been used to 
evaluate IC/PBS 
patients prior to this 
study.   Treatment of IC 
has a significant effect 
on QOL and QOL can be 
used to evaluate 
success of treatment.  
A QOL questionnaire 
specific to IC needs to 
be developed and 
validated.  CyA therapy 
has a greater impact on 
the majority of the 
categories of QOL 
measurements than 
PPS.   
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(Sand et al., 
2008) 
Secondary analysis of 
RCT/2- 
Retrospective 
secondary analysis of a 
previously published 
32-week multi center 
randomized, double 
blind, parallel-group 
clinical trial of 380 
women.  A subset of 
128 women who 
received PPS 
300mg/day were 
analyzed for treatment 
response using they 
O’Leary-Sant ICSI and a 
treatment satisfaction 
questionnaire.  Women 
were labeled as 
responding to PPS 
treatment if they had a 
greater than or equal to 
30% reeducation in the 
ICSI score from 
baseline.   
The original RCT did not 
have a placebo group 
and the treatment 
satisfaction 
questionnaire is not a 
validated instrument.  
However the O’Leary-
Sant ICSI is validated for 
the evaluation of IC 
symptoms.  91% of 
subjects were women 
with moderate or sever 
symptoms at baseline, 
making it difficult to 
generalize this data to a 
population of IC patients 
with mild symptoms.  
The sub-sample from the 
original RCT analyzed in 
this study was relatively 
small (n=128).  
49 women (42%) with 
a greater than 30% 
reduction in ICSI score 
from baseline were 
identified as 
responders to PPS 
treatment.  These 
women were more 
likely to be pleased 
with PPS for 
treatment of IC 
symptoms 
(p<0.00101), to have 
benefitted from PPS 
(p<0.0001) and to 
recommend PPS to 
other patients with 
similar symptoms 
(p=0.0466). 79% of 
responders found 
that PPS provided 
better relief than 
other treatments 
tried (p=0.0038).  
Among all subjects 
more than 70% 
reported a benefit 
from PPS at the end 
of the treatment 
period, even if they 
were not identified as 
70% of subjects 
reported a benefit from 
PPS including more 
than a third of those 
classified as non-
responders.  Many 
participants also 
reported greater 
symptom relief with 
PPS compared to 
previous treatments for 
IC symptoms.  A 
significantly higher rate 
of symptom reduction 
and satisfaction was 
reported with PPS 
therapy.  PPS therapy 
has a significant 
positive correlation 
between ICSI score and 
the patient response 
score on the individual 
questions in the patient 
treatment 
questionnaire.   
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responders. This 
suggests that even 
non-responders 
would have ICSI 
scores showing a 
trend toward 
improvement.  A 
substantial 
proportion of non-
responders also 
reported that they 
relief that they found 
with PPS was greater 
than the relief that 
they had found with 
previous treatments 
for IC.   
(Schmid et al., 
2011) 
Cohort study/ 2- 69 female patients 
diagnosed with IC based 
on the NIDDK standards 
and histories of 
unsuccessful treatment 
were included.  Patients 
were evaluated prior to 
treatment and two 
weeks after each step in 
the treatment 
algorithm for sexual 
functioning, and quality 
of life.  If a patient was 
satisfied with current 
treatment it was 
Using the NIDDK criteria 
may limit the number 
and type of IC patients 
that were included in the 
study.  In addition using 
patients who had 
histories of failures with 
other treatments might 
suggest that these 
patients have more 
severe symptoms that 
the general population 
of IC patients.   
Researchers found 
that a stepwise 
approach to 
management if 
symptoms with 
tetracycline, oral 
steroids, and 
antihistamines 
significantly improved 
sexual function and 
quality of life in 
women with IC/PBS.  
VAS scores for pain 
improved significantly 
after receiving 
This study shows that a 
stepwise approach to 
therapy with 
tetracycline, bladder 
instillation with 
heparin/local 
anesthetic, oral 
steroids, 
antihistamines, and 
DMSO instillation 
significantly improved 
sexual function and 
quality of life in IC 
patients.  Improvement 
in all domains of sexual 
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considered a success 
and the patient did not 
progress to the next 
step of the algorithm, if 
the patient continued 
to have symptoms the 
next step was 
implemented. The 
King’s Health 
Questionnaire was used 
to assess quality of life 
and the visual analogue 
scale (VAS) 0-10 was 
used o assess symptom 
bother.  A two-tailed t 
test was performed to 
compare scores before 
and after treatment. 
 
treatment (p<0.001), 
as did nocturia 
(p<0.01) and 
frequency (p<0.01).  
However, Urgency 
was not significantly 
improved using this 
treatment algorithm 
(p=0.09).  All domains 
of the King’s Health 
Questionnaire 
showed significant 
improvement 
(p<0.001) with the 
exception of 
incontinence impact 
(p=0.227).  
function and quality of 
life cannot be achieved.  
Long-term follow-up 
and research on the 
etiology of IC needs to 
be conducted to 
determine efficient 
therapy.   
(Shorter, 2006) Expert opinion with 
case study/ 4 
This article presents a 
case study and a 
summary of the 
literature about the role 
of diet in the 
management of IC. 
Which as the author 
admits is limited to 
anecdotal reports by 
patients and experts.   
The author does not 
describe her search of 
the evidence therefore it 
is hard to grade the 
strength of her 
recommendations.  
Based the author’s own 
report high quality 
evidence to support diet 
modifications in IC 
appears to be lacking.   
Data gathered from 
patients and experts 
on dietary changes 
affect on IC 
symptoms is 
anecdotal.  However, 
it does show that 
eliminating certain 
foods does decrease 
pain associated with 
IC in most patients.  
Dietary treatment is 
complicated because 
There are limited 
studies on the effect of 
diet on IC.  However, 
the majority of IC 
patients have found 
that certain foods can 
exacerbate symptoms.  
The IC association (ICA) 
has created an IC diet 
based on anecdotal 
information from 
patients and urologist.  
Foods that are 
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it must be 
individualized and 
requires keeping a 
food intake and 
voiding diary.  Foods 
should be eliminated 
and then 
systematically 
reintroduced to 
determine which are 
the offending items.  
A concern is that by 
eliminating foods or 
whole food groups 
patients may become 
deficient in some 
nutrients.    
commonly found to 
exacerbate symptoms 
include alcoholic 
beverages, coffee, tea, 
carbonated beverages, 
tomatoes, and certain 
spices.  Diets should be 
individualized and 
patients should be 
careful not to eliminate 
too many foods as that 
may cause deficiencies 
in essential nutrients.   
(Tettamanti et 
al., 2011) 
Case control twin 
study/ 2- 
Female twins with IC 
were matched with 
healthy twin controls. 
Logistical regression 
models with a 95% 
confidence interval 
were used to evaluate 
the effect of smoking, 
coffee and tea 
consumption on 
symptoms of IC.     
Twin controls were used 
to minimize confounding 
factors.  Disease and 
exposure are measured 
at the same time; 
therefore conclusions 
about whether the 
exposure preceded or 
resulted from the 
disease cannot be made.   
Smoking currently or 
formerly and tea 
consumption were 
associated with 
significantly higher 
cases of IC symptoms.  
Smoking as a risk 
factor was 
confounded by 
familial factors.  
Coffee consumption 
was not associated 
with a higher risk of IC 
symptoms.   
Tea and smoking are 
positively associated 
with IC but the 
association of smoking 
with IC is likely to be 
confounded by genetic 
factors.  The 
association with tea 
consumption is not 
confounded by familial 
factors.  Coffee 
consumption does not 
have a significant 
association with IC 
symptoms.   
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(Theoharides, 
2007) 
Literature review/4 The methods used to 
conduct this literature 
review are not 
discussed.   
Inclusion and exclusion 
criteria of articles used 
for this review are not 
provided.  Neither is a 
discussion of the 
strength of the literature 
available.  Studies 
reviewed are referenced 
and described briefly; 
comments about the 
strength of individual 
studies are discussed 
briefly.   However, the 
reader must draw 
his/her own conclusion 
about the strength of 
body of literature 
reviewed.   
There is no benefit in 
the form of pain relief 
from the practice of 
raising the pH of urine 
through diet 
modifications or 
supplements.  Clinical 
trials to date have 
used adult patients 
with varying degrees 
of severity of IC 
symptoms and 
durations of the 
disease, making it 
difficult to draw 
definitive conclusions 
about the treatments 
studied.  Many of the 
studies that have 
been conducted are 
small and the results 
should be considered 
suggestive not 
conclusive.   
There is no curative 
treatment available for 
IC.  Currently the 
available literature on 
definitive treatment for 
IC is lacking.  
Intravesical DMSO, oral 
amitriptyline, PPS and 
hydroxyzine have 
variable results.  The 
most successful 
treatment is likely with 
a combination of these 
treatments. 
(Unwin, 2011) Review of literature/ 
3 
 
The author does not 
discuss details of the 
literature search 
process.  However, each 
recommendation is 
rated based on the 
This is a summary of 
current literature 
without 
recommendations made 
by the author.  Threats 
to validity are related to 
IC/PBS is considered 
in the patient the 
otherwise 
unexplained pelvic 
area pain, urinary 
frequency and 
After establishing 
diagnosis PPS is a 
baseline treatment 
additional multimodal 
treatments can be used 
as indicated.  
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strength of the 
evidence, for example a 
rating of an A is, 
“consistent quality 
patient oriented 
evidence” and C is 
based on, “consensus 
disease oriented 
evidence, usually expert 
opinions”  
the fact that the method 
of literature review is 
unavailable.   
urgency, diagnosis is 
confirmed with 
cystoscopy.  Oral 
therapy with PPS and 
amitriptyline and 
bladder installation of 
DMSO are the 
cornerstones of 
treatment.   
Amitriptyline is safe 
and effective for pain 
relief.  Non-
pharmacologic 
strategies such as 
bladder training, diet 
change, counseling, 
and physical therapy 
may be helpful but 
have not been studied 
in clinical trials.   
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APPENDIX B 
Table B.1: SIGN 50 Levels of Evidence  
 
Levels of Evidence 
1++ High quality meta-analyses, systematic reviews 
of RCTs or RCTs with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic 
reviews, or RCTs with a low risk of bias 
1- Meta-analysis, systematic reviews, or RCTs 
with a high risk of bias 
2++ High quality systematic reviews of case control 
or cohort studies, high quality case control or 
cohort studies with a very low risk of 
confounding or bias and a high probability that 
the relationship is causal 
2+ Well-conducted case control or cohort studies 
with a low risk of confounding or bias and 
moderate probability that the relationship is 
causal.  
2- Case control or cohort studies with a high risk 
of confounding or bias and significant risk that 
the relationship is not causal 
3 Non-analytic studies, example: case reports, 
case series 
4 Expert opinion 
(SIGN, 2011)
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APPENDIX C 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from the AUA Interstitial Cystitis (2011). Hanno, P. M., Burks, D. A., Clemens, J. Q., Dmochowski, R. R., Erickson, D. FitzGerald, M. P., Forrest, J. B., Gordon, B., 
Gray, M., Mayer, R. D., Newman, D., Nyberg Jr., L., Payne, C. K., Wesselmann, U., Faraday, M. M.:Guideline on the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome 
(2011).  American Urological Association Education and Research, Inc., ©2011 http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=ic-bps 
 
Figure C.1: AUA Guideline Algorithm  
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APPENDIX D 
Table D.1: SIGN 50 Grades of Recommendations  
Grade Explanation 
A At least one meta-analysis, systematic review, 
or RCT rated as 1++ and directly applicable to 
the target population.  Or 
A body of evidence consisting principally of 
studies rated as 1+, directly applicable to the 
target population, and demonstrating overall 
consistency of results.   
B A body of evidence including studies rated as 
2++ directly applicable to the target population 
and demonstrating overall consistency of 
results; or Extrapolated evidence from studies 
rated as 1++ or 1+ 
C A body of evidence including studies rated as 
2+, directly applicable to the target population 
and demonstrating overall consistency of 
results; or Extrapolated evidence from studies 
rated as 2++ 
D Evidence level 3 or 4; or extrapolated evidence 
from studies rated as 2+ 
 
(SIGN, 2011) 
